Page last updated: 2024-11-08

xanthohumol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

xanthohumol: from hop plant, Humulus lupulus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

xanthohumol : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4', a methoxy group at position 6' and a prenyl group at position 3'. Isolated from Humulus lupulus, it induces apoptosis in human malignant glioblastoma cells. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
HumulusgenusA plant genus in the CANNABACEAE family. Best known for the buds of Humulus lupulus L. used in BEER.[MeSH]CannabaceaeA plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. It is most notable for the members, Cannabis and Hops.[MeSH]
Humulus lupulusspecies[no description available]CannabaceaeA plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. It is most notable for the members, Cannabis and Hops.[MeSH]

Cross-References

ID SourceID
PubMed CID639665
CHEMBL ID253896
CHEBI ID66331
CHEBI ID94745
SCHEMBL ID143683
MeSH IDM0273009

Synonyms (53)

Synonym
(e)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one
1-(2,4-dihydroxy-6-methoxy-3-(3-methyl-2-butenyl)phenyl)-3-(4-hydroxyphenyl)-2-propen-1-one
6754-58-1
MEGXP0_000104
ACON1_001634
NCGC00180304-01
SMP2_000278
inchi=1/c21h22o5/c1-13(2)4-10-16-18(24)12-19(26-3)20(21(16)25)17(23)11-7-14-5-8-15(22)9-6-14/h4-9,11-12,22,24-25h,10h2,1-3h3/b11-7
xanthohumol
(2e)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one
xanthohumol from hop (humulus lupulus), >=96% (hplc)
xantho-flav
(2e)-1-(2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl)-3-(4-hydroxyphenyl)-2-propen-1-one
LMPK12120294
CHEMBL253896
chebi:66331 ,
bdbm50384998
2-propen-1-one, 1-(2,4-hydroxy-6-methoxy-3-(3-methyl-2-butenyl)phenyl)-3-(4-hydroxyphenyl)-, (e)-
t4467yt1nt ,
unii-t4467yt1nt
2',4,4'-trihydroxy-6'-methoxy-3'-prenylchalcone
AKOS016010098
(e)-1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-butenyl)phenyl]-3-(4-hydroxyphenyl)propenone
xanthohumol from hop (humulus lupulus)
S7889
X0068
BRD-K77390737-001-01-6
xanthohumol [inci]
(e)-1-(2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
SCHEMBL143683
ORXQGKIUCDPEAJ-YRNVUSSQSA-N
569-83-5
1-(2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
(2e)-1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one
AC-31276
xanthohumol, primary pharmaceutical reference standard
CHEBI:94745
mfcd00210576
BCP18498
DTXSID00893171
Q408088
Q27166535
1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one
(e)-1-(2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
DB15359
BS-17392
xanthohumol(random configuration)
HMS3886H19
CCG-268086
A867246
xanthohumol(randomconfiguration)
2-propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2e)-
AKOS040762512

Research Excerpts

Overview

Xanthohumol (XN) is a prenylated flavonoid known for its antioxidant and anti-inflammatory effects. It is extracted in a high concentration from the hard resin of hops (Humulus lupulus L.), the basic raw material of beer.

ExcerptReferenceRelevance
"Xanthohumol (1) is a principal prenylated chalcone found in hops. "( Xanthohumol Blocks Proliferation and Migration of Vascular Smooth Muscle Cells in Vitro and Reduces Neointima Formation in Vivo.
Atanasov, AG; Breuss, JM; Dirsch, VM; Heiss, EH; Jiang, B; Liu, R; Liu, W; Schachner, D, 2017
)
3.34
"Xanthohumol (XN) is an important natural product of hops ("( Xanthohumol Induces ROS through NADPH Oxidase, Causes Cell Cycle Arrest and Apoptosis.
Cao, XH; Chen, J; Hu, SS; Li, Z; Mi, XQ; Shi, X; Wang, CM; Zhang, SQ; Zhao, J, 2021
)
2.79
"Xanthohumol (XN) is a prenylated flavonoid known for its antioxidant and anti-inflammatory effects and has been studied as an anti-cancer agent. "( Xanthohumol reduces inflammation and cell metabolism in HT29 primary colon cancer cells.
Alorda-Clara, M; Martínez-Vigara, M; Oliver, J; Pons, DG; Roca, P; Sastre-Serra, J; Torrens-Mas, M, 2022
)
3.61
"Xanthohumol (Xn) is a compound extracted in a high concentration from the hard resin of hops (Humulus lupulus L.), the basic raw material of beer."( Xanthohumol targets the JNK1/2 signaling pathway in apoptosis of human nasopharyngeal carcinoma cells.
Chen, MK; Chou, MC; Chuang, YC; Hsieh, MJ; Hsieh, MY; Lin, CC; Lo, YS, 2022
)
2.89
"Xanthohumol is an active ingredient in Traditional Chinese Medicines Hops (Humulus lupulus L.)."( Xanthohumol inhibits non-small cell lung cancer by activating PUMA-mediated apoptosis.
Jiang, Z; Jin, L; Li, X; Ma, Y; Tang, H; Tong, X, 2022
)
2.89
"Xanthohumol (XN) is a prenylated plant polyphenol that naturally occurs in hops and its products, e.g. "( Xanthohumol exerts anti-inflammatory effects in an in vitro model of mechanically stimulated cementoblasts.
Bhargava, S; Craveiro, RB; Jankowski, J; Niederau, C; Schneider-Kramman, R; Wolf, M, 2022
)
3.61
"Xanthohumol is a hop-derived flavonoid that has been widely examined for its health-protecting and antitumorigenic properties, but not yet in a natural beer matrix. "( Xanthohumol-Enriched Beer Does Not Exert Antitumorigenic Effects on HeLa Cell Line In Vivo.
Balogh, L; Benedek, C; Brányik, T; Csajbókné Csobod, É; Éliás, AJ; Mák, E; Veresné Bálint, M, 2023
)
3.8
"Xanthohumol is a principal prenylated chalcone isolated from hops. "( Xanthohumol inhibits non-small cell lung cancer via directly targeting T-lymphokine-activated killer cell-originated protein kinase.
Cao, L; Chen, H; Cui, J; Han, K; Hu, H; Ma, C; Ma, X; Yin, S; Zhao, C; Zhao, S, 2023
)
3.8
"Xanthohumol (Xan) is a prenylated chalcone mainly found in hops; it has been demonstrated to function against hypercholesterolemia, hyperlipidemia, and atherosclerosis. "( Xanthohumol Suppresses NPC1L1 Gene Expression through Downregulation of HNF-4α and Inhibits Cholesterol Uptake in Caco-2 Cells.
Chen, PY; Gao, WY; Pan, MH; Thang, SK; Wu, MJ; Yen, JH, 2019
)
3.4
"Xanthohumol is a natural product derived from hops (Humulus lupulus L.), which is reported to have glutamate release-inhibiting activity."( Xanthohumol, an active constituent from hope, affords protection against kainic acid-induced excitotoxicity in rats.
Ho, YH; Hung, CF; Kuo, JR; Wang, CC; Wang, SJ, 2020
)
2.72
"Xanthohumol is a prenylated flavonoid of plant origin and has been reported to exhibit a spectrum of pharmacological properties including anticancer effects. "( Xanthohumol chalcone acts as a powerful inhibitor of carcinogenesis in drug-resistant human colon carcinoma and these effects are mediated via G2/M phase cell cycle arrest, activation of apoptotic pathways, caspase activation and targeting Ras /MEK/ERK pa
An, LJ; Guo, J; Li, Y; Liu, X; Lv, X; Song, AL; Wang, Y; Zhao, L,
)
3.02
"Xanthohumol (XN) is a most abundant prenylated flavonoid present in hops."( Pharmacokinetics of xanthohumol in rats of both sexes after oral and intravenous administration of pure xanthohumol and prenylflavonoid extract.
Bobak, Ł; Dziewiszek, W; Huszcza, E; Kwiatkowska, J; Matuszewska, A; Nowak, B; Popłoński, J; Poźniak, B; Szeląg, A, 2020
)
1.6
"Xanthohumol (XN) is a potential bioactive substance for the prevention and treatment of many diseases."( Xanthohumol prolongs lifespan and decreases stress-induced mortality in Drosophila melanogaster.
Dechakhamphu, A; Wongchum, N, 2021
)
2.79
"Xanthohumol (XAN) is a unique component of Humulus lupulus L. "( Xanthohumol ameliorates memory impairment and reduces the deposition of β-amyloid in APP/PS1 mice via regulating the mTOR/LC3II and Bax/Bcl-2 signalling pathways.
Guo, YX; Han, T; Li, XJ; Rahmand, K; Sun, XL; Wang, GP; Wang, NN; Xia, TS; Xin, HL; Xu, LC; Zhang, JB, 2021
)
3.51
"Xanthohumol (XH) is an important prenylated flavonoid that is found within the inflorescence of "( Xanthohumol for Human Malignancies: Chemistry, Pharmacokinetics and Molecular Targets.
Bishayee, A; Haque, E; Harish, V; Jamieson, S; Śmiech, M; Taniguchi, H; Tewari, D, 2021
)
3.51
"Xanthohumol is a prenylated flavonoid found in hops (Humulus lupulus) and beer."( Cytoprotective effects of xanthohumol against methylglyoxal-induced cytotoxicity in MC3T3-E1 osteoblastic cells.
Choi, EM; Chon, S; Suh, KS, 2018
)
1.5
"Xanthohumol is a prenylated flavonoid found in hops (Humulus lupulus) and beer."( Xanthohumol ameliorates 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced cellular toxicity in cultured MC3T3-E1 osteoblastic cells.
Chin, SO; Choe, W; Choi, EM; Chon, S; Ha, J; Kim, HS; Pak, YK; Park, SY; Rhee, SY; Suh, KS, 2018
)
2.64
"Xanthohumol (XN) is a hop-derived prenylflavonoid and have been reported to exhibit anticancer properties in several types of cancer. "( Xanthohumol, a hop-derived prenylflavonoid present in beer, impairs mitochondrial functionality of SW620 colon cancer cells.
Ahmiane, Y; Oliver, J; Pons, DG; Roca, P; Sastre-Serra, J, 2019
)
3.4
"Xanthohumol (XN) is a bioactive prenylflavonoid from hops. "( Human pharmacokinetics of xanthohumol, an antihyperglycemic flavonoid from hops.
Bobe, G; Choi, J; Christensen, JM; Karnpracha, C; Legette, L; Purnell, JQ; Reed, RL; Rodriguez-Proteau, R; Stevens, JF, 2014
)
2.15
"Xanthohumol is a major prenylated, hydrophobic flavonoid found in the female inflorescences of the hop plant (Humulus lupulus L.). "( Effects of xanthohumol-rich hop extract on the differentiation of preadipocytes.
Kiyofuji, A; Osada, K; Takahashi, K; Yui, K, 2014
)
2.23
"Xanthohumol (XN) is a unique prenylated flavonoid in hops (Humulus lupulus L.) and beer. "( Xanthohumol, a prenylated chalcone from beer hops, acts as an α-glucosidase inhibitor in vitro.
Dong, J; Liu, G; Liu, M; Miao, J; Qian, Z; Yin, H, 2014
)
3.29
"Xanthohumol is a prenylated flavonoid that has been shown to increase beta-oxidation in the livers of rodents, decreasing circulating free fatty acids in the serum."( Xanthohumol improved cognitive flexibility in young mice.
Choi, J; Elias, V; Legette, LL; Magnusson, KR; Stevens, JF; Zamzow, DR, 2014
)
2.57
"Xanthohumol (XN) is a natural anticancer compound that inhibits the proliferation of oestrogen receptor-α (ERα)-positive breast cancer cells. "( Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions.
Honda, J; Imoto, M; Katagiri, T; Komatsu, M; Miyoshi, Y; Osada, H; Sasa, M; Tashiro, E; Yoshimaru, T, 2014
)
3.29
"Xanthohumol is a prenylflavonoid extracted from hops (Humulus lupulus). "( Xanthohumol induces generation of reactive oxygen species and triggers apoptosis through inhibition of mitochondrial electron transfer chain complex I.
Chu, W; Liu, Y; Wei, P; Wei, T; Zhang, B, 2015
)
3.3
"Xanthohumol (XN) is a hop flavonoid found in beers and refreshment drinks. "( Impact of xanthohumol (a prenylated flavonoid from hops) on DNA stability and other health-related biochemical parameters: Results of human intervention trials.
Al-Serori, H; Biendl, M; Bono, R; Ferk, F; Henriksen, T; Jäger, W; Knasmüller, S; Kundi, M; Marculescu, R; Mišík, M; Nersesyan, A; Pichler, C; Poulsen, HE; Romanazzi, V; Szekeres, T; Wagner, KH, 2016
)
2.28
"Xanthohumol (XN) is a prenylated flavonoid found in hops (Humulus lupulus) and beer. "( Xanthohumol improves dysfunctional glucose and lipid metabolism in diet-induced obese C57BL/6J mice.
Choi, J; Elias, VD; Hay, JJ; Miranda, CL; Reed, RL; Stevens, JF, 2016
)
3.32
"Xanthohumol (XN) is a hop flavonoid contained in beers and soft drinks. "( Xanthohumol Prevents DNA Damage by Dietary Carcinogens: Results of a Human Intervention Trial.
Al-Serori, H; Ferk, F; Herbacek, I; Huber, W; Jäger, W; Knasmueller, S; Kundi, M; Mišík, M; Nersesyan, A; Pichler, C; Waldherr, M, 2017
)
3.34
"Xanthohumol (Xan) is a natural constituent of human nutrition. "( The antileishmanial activity of xanthohumol is mediated by mitochondrial inhibition.
Gille, L; Jäger, W; Lackova, A; Monzote, L; Pichler, G; Staniek, K; Steinbauer, S, 2017
)
2.18
"Xanthohumol (XN) is a major chalcone found in hop, which is used to add bitterness and flavor to beer. "( Increased IL-2 production in T cells by xanthohumol through enhanced NF-AT and AP-1 activity.
Choi, HJ; Choi, JM; Kang, BY; Kim, HJ; Lee, IS; Lee, KY, 2009
)
2.06
"Xanthohumol is a proapoptotic hop-derived beer component with anticancer and antimicrobial activities. "( Inhibition of suicidal erythrocyte death by xanthohumol.
Föller, M; Lang, F; Mahmud, H; Qadri, SM, 2009
)
2.06
"Xanthohumol (XN) is a natural compound with potential antiviral activity. "( Inhibition of bovine viral diarrhea virus in vitro by xanthohumol: comparisons with ribavirin and interferon-alpha and implications for the development of anti-hepatitis C virus agents.
Chen, J; Han, Q; Liu, Z; Lou, S; Qiu, J; Zhang, G; Zhang, N, 2009
)
2.04
"Xanthohumol (XN) is a natural compound with multifunctional potentials, including antiviral activity. "( Xanthohumol enhances antiviral effect of interferon alpha-2b against bovine viral diarrhea virus, a surrogate of hepatitis C virus.
Chen, J; Han, Q; Liu, Z; Lv, Y; Zhang, N, 2010
)
3.25
"Xanthohumol (XN) is a major prenylated chalcone found in hops, which is used to add bitterness and flavor to beer. "( Xanthohumol, a chalcon derived from hops, inhibits hepatic inflammation and fibrosis.
Dorn, C; Gehrig, M; Heilmann, J; Hellerbrand, C; Kraus, B; Motyl, M; Schölmerich, J; Weiss, TS, 2010
)
3.25
"Xanthohumol is a potent Raf-1 activator in MTC cells. "( Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer.
Chen, H; Cook, MR; Kunnimalaiyaan, M; Luo, J; Ndiaye, M, 2010
)
3.25
"Xanthohumol (XN) is a prenylated chalcone-type flavonoid found in hops and beer. "( Xanthohumol and related prenylated flavonoids inhibit inflammatory cytokine production in LPS-activated THP-1 monocytes: structure-activity relationships and in silico binding to myeloid differentiation protein-2 (MD-2).
Hobbs, DJ; Miranda, CL; Peluso, MR; Proteau, RR; Stevens, JF, 2010
)
3.25
"Xanthohumol is a flavonoid isolated from the hop plant Humulus lupulus L., with anti-microbial, antioxidant, anti-inflammatory, and anti-carcinogenic properties."( Direct inhibition of elastase and matrixmetalloproteinases and stimulation of biosynthesis of fibrillar collagens, elastin, and fibrillins by xanthohumol.
Arena, R; Chen, YJ; Conte, J; Gonzalez, S; Haas, G; Natarajan, P; Natrajan, P; Philips, N; Samuel, M,
)
1.05
"Xanthohumol (XN) is a hop derived prenylated flavonoid contained in beer. "( Xanthohumol, a prenylated flavonoid contained in beer, prevents the induction of preneoplastic lesions and DNA damage in liver and colon induced by the heterocyclic aromatic amine amino-3-methyl-imidazo[4,5-f]quinoline (IQ).
Bichler, J; Ferk, F; Filipic, M; Grasl-Kraupp, B; Haslinger, E; Huber, WW; Knasmüller, S; Misík, M; Nersesyan, A; Zegura, B, 2010
)
3.25
"Xanthohumol was found to be a potent chemopreventive agent; however, no data are available concerning its neuroprotective effects."( Neuroprotective effects of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus), in ischemic stroke of rats.
Chou, DS; Hsiao, G; Hsieh, CY; Hsu, CK; Lu, WJ; Sheu, JR; Wu, GJ; Yen, TL, 2012
)
1.4
"Xanthohumol is a prenylated flavonoid isolated from hops, which is known to act as a pleiotropic cancer chemopreventive agent owing to its anti-proliferative, anti-inflammatory and anti-angiogenic properties. "( Xanthohumol inhibits growth and vascularization of developing endometriotic lesions.
Körbel, C; Laschke, MW; Menger, MD; Rudzitis-Auth, J; Scheuer, C, 2012
)
3.26
"Xanthohumol is expected to be a potent anti-atherosclerotic agent due to its inhibition of cholesteryl ester transfer protein (CETP). "( Xanthohumol prevents atherosclerosis by reducing arterial cholesterol content via CETP and apolipoprotein E in CETP-transgenic mice.
Chiba, H; Hirata, H; Kobayashi, N; Ozaki, M; Segawa, S; Shigyo, T, 2012
)
3.26
"Xanthohumol was found to be a more potent antiviral agent against these viruses than the isomer iso-xanthohumol."( Antiviral activity of hop constituents against a series of DNA and RNA viruses.
Beer, BB; Buckheit, RW; Buckwold, VE; Chuvala, L; Hartman, T; Nalca, A; Pallansch, M; Paulman, R; Ptak, R; Russell, J; Sloane, S; Smith, RJ; Turpin, JA; Voss, TG; Walton, EM; Ward, P; Wei, J; Wells, J; Wenzel-Mathers, M; Wilson, RJ, 2004
)
1.04
"Xanthohumol (XN) is a prenylated chalcone, which has been shown to possess a broad range of potential cancer preventive and additional biological activities. "( A safety study of oral xanthohumol administration and its influence on fertility in Sprague Dawley rats.
Becker, H; Frank, N; Gerhäuser, C; Hussong, R; Ittrich, C; Knauft, J; Owen, R, 2005
)
2.08
"Xanthohumol (XN) is a prenylated chalcone with antimutagenic and anticancer activity from hops. "( Determination of xanthohumol in hops (Humulus lupulus L.) by nonaqueous CE.
Filipic, M; Kac, J; Kreft, S; Mlinaric, A; Zakrajsek, J, 2007
)
2.12
"As xanthohumol is known to be an effective inhibitor of cytochrome P450 enzymes and an inducer of NAD(P)H: quinone reductase (QR), our findings can be explained by an inhibition of metabolic activation of pro-carcinogens and/or by induction of carcinogen-detoxifying and anti-oxidative enzymes by xanthohumol."( Protective effects of xanthohumol against the genotoxicity of benzo(a)pyrene (BaP), 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and tert-butyl hydroperoxide (t-BOOH) in HepG2 human hepatoma cells.
Filipic, M; Lah, TT; Plazar, J; Zegura, B, 2007
)
1.17

Effects

Xanthohumol (XN) has emerged as a potential compound that inhibits various types of cancer, but the molecular mechanism underlying the effects of XN remains unclear. It has capability of scavenging free radicals, suggesting its potential for the prevention of neurodegeneration.

ExcerptReferenceRelevance
"Xanthohumol (XN) has various effects, including anti-inflammation and anti-cancer; however, the detailed mechanism of TGF-β signaling has not yet been studied."( Xanthohumol Interferes with the Activation of TGF-β Signaling in the Process Leading to Intestinal Fibrosis.
Han, YM; Kim, EH; Kim, HS; Kim, SH; Lee, DY; Song, MY; Yun, SM, 2022
)
2.89
"Xanthohumol (XN) has numerous compelling physiological activities, but the poor solubility and stability severely limit its utilization. "( Sophorolipid-based microemulsion delivery system: Multifaceted enhancement of physicochemical properties of xanthohumol.
Chen, Q; Guo, Z; Ji, S; Liu, Y; Lu, B; Luo, J; Wang, Y; Yang, B; Yang, X; Zhao, T, 2023
)
2.57
"Xanthohumol has the ability of repairing cognitive impairment through removing the inhibition of miR-532-3p on Mpped1 in mouse hippocampus. "( Xanthohumol improves cognitive impairment by regulating miRNA-532-3p/Mpped1 in ovariectomized mice.
Cao, W; Li, C; Li, J; Liu, Y; Qiao, R; Shao, J, 2023
)
3.8
"Xanthohumol has been reported to have cytoprotection through activation of Nrf2-ARE signaling pathway and; it has capability of scavenging free radicals, suggesting its potential for the prevention of neurodegeneration. "( Amyloid-β Aggregation Inhibitory and Neuroprotective Effects of Xanthohumol and its Derivatives for Alzheimer's Diseases.
Ho, SL; Li, HW; Poon, CY; Wang, X; Wong, MS; Yan, T, 2019
)
2.2
"Xanthohumol (XN) has emerged as a potential compound that inhibits various types of cancer, but the molecular mechanism underlying the effects of XN remains unclear."( Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells.
Gamblin, TC; Kunnimalaiyaan, M; Kunnimalaiyaan, S; Trevino, J; Tsai, S, 2015
)
2.58
"Xanthohumol further has anti-inflammatory activity."( Triggering of dendritic cell apoptosis by xanthohumol.
Götz, F; Gu, S; Gulbins, E; Lang, F; Shumilina, E; Xuan, NT, 2010
)
1.35
"Xanthohumol has anti-carcinogenic, free radical-scavenging, and anti-inflammatory activities, but its precise mechanisms are not clarified yet."( Anti-inflammatory activity of xanthohumol involves heme oxygenase-1 induction via NRF2-ARE signaling in microglial BV2 cells.
Choi, HJ; Gal, J; Kang, BY; Kang, JC; Kim, HJ; Lee, IS; Lim, J, 2011
)
1.38
"Xanthohumol has been shown to inhibit cancer cell growth and invasion, including Kaposi's sarcoma, which also highly expresses Notch1."( Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines.
Drenzek, JG; Jaskula-Sztul, R; Rausch, MM; Rose, SL; Seiler, NL, 2011
)
2.53
"Xanthohumol has been characterized a 'broad-spectrum' cancer chemopreventive agent in in vitro studies, while 8-prenylnaringenin enjoys fame as the most potent phytoestrogen known to date."( Xanthohumol and related prenylflavonoids from hops and beer: to your good health!
Page, JE; Stevens, JF, 2004
)
2.49
"Xanthohumol (Xn) has well-established chemopreventive potential in vitro. "( Biosynthetic (14)C-labelling of xanthohumol in hop cones.
Becker, H; Berwanger, S; Frank, N; Knauft, J, 2005
)
2.05
"Xanthohumol (XA) has recently been documented to have an impact on breast cancer cell growth and invasiveness in vitro."( Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism.
Bracke, M; Janssens, A; Lust, S; Offner, F; Philippe, J; Vanhoecke, B, 2005
)
2.49

Actions

ExcerptReferenceRelevance
"Xanthohumol was able to inhibit the invasion of MCF-7/6 cells at 5 microM in the chick heart invasion assay and of T47-D cells in the collagen invasion assay."( Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops (Humulus lupulus L.) and beer.
Bracke, M; De Keukeleire, D; Depypere, H; Derycke, L; Van Marck, V; Vanhoecke, B, 2005
)
1.36

Treatment

Xanthohumol treatment was unable to affect the palmitoylation of NMDA receptor subunits and associated proteins assessed in this study. Pretreatment with xanthohomol before MG exposure reduced MG-induced mitochondrial dysfunction. Xanthohamol reversed the cognitive decline of OVX mice according to behavioral tests.

ExcerptReferenceRelevance
"Xanthohumol treatment reversed the cognitive decline of OVX mice according to behavioral tests. "( Xanthohumol improves cognitive impairment by regulating miRNA-532-3p/Mpped1 in ovariectomized mice.
Cao, W; Li, C; Li, J; Liu, Y; Qiao, R; Shao, J, 2023
)
3.8
"Xanthohumol treatment was unable to affect the palmitoylation of NMDA receptor subunits and associated proteins assessed in this study."( Xanthohumol improved cognitive flexibility in young mice.
Choi, J; Elias, V; Legette, LL; Magnusson, KR; Stevens, JF; Zamzow, DR, 2014
)
2.57
"Xanthohumol treatment produced a marked reduction in infarct size compared to that in control rats."( Neuroprotective effects of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus), in ischemic stroke of rats.
Chou, DS; Hsiao, G; Hsieh, CY; Hsu, CK; Lu, WJ; Sheu, JR; Wu, GJ; Yen, TL, 2012
)
1.4
"Pretreatment with xanthohumol before MG exposure reduced MG-induced mitochondrial dysfunction."( Cytoprotective effects of xanthohumol against methylglyoxal-induced cytotoxicity in MC3T3-E1 osteoblastic cells.
Choi, EM; Chon, S; Suh, KS, 2018
)
1.1
"Treatment with xanthohumol inhibited ESCC cell growth and induced apoptosis and cell cycle arrest at the G1 phase."( Targeted therapy of the AKT kinase inhibits esophageal squamous cell carcinoma growth in vitro and in vivo.
Bode, AM; Chen, H; Dong, Z; Lee, MH; Li, E; Liu, F; Liu, K; Liu, X; Shi, Y; Song, M; Wang, P; Yang, R; Zhang, M; Zhao, R, 2019
)
0.85
"Treatment with xanthohumol (0.2 and 0.4 mg/kg; intraperitoneally) 10 min before MCAO dose-dependently attenuated focal cerebral ischemia and improved neurobehavioral deficits in cerebral ischemic rats."( Neuroprotective effects of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus), in ischemic stroke of rats.
Chou, DS; Hsiao, G; Hsieh, CY; Hsu, CK; Lu, WJ; Sheu, JR; Wu, GJ; Yen, TL, 2012
)
1.02

Toxicity

ExcerptReferenceRelevance
" per day), given either for 4 wk prior to or during mating, gestation, and nursing, did not cause any adverse effects on female reproduction and the development of offspring."( A safety study of oral xanthohumol administration and its influence on fertility in Sprague Dawley rats.
Becker, H; Frank, N; Gerhäuser, C; Hussong, R; Ittrich, C; Knauft, J; Owen, R, 2005
)
0.64
" To ensure a safe and effective product, botanical dietary supplements should be developed in a manner analogous to pharmaceuticals that involves identification of mechanisms of action and active constituents, chemical standardization based on the active compounds, biological standardization based on pharmacological activity, preclinical evaluation of toxicity and potential for drug-botanical interactions, metabolism of active compounds, and finally, clinical studies of safety and efficacy."( Development of Safe and Effective Botanical Dietary Supplements.
van Breemen, RB, 2015
)
0.42
"Over an eight-week period, 24 mg daily xanthohumol was safe and well-tolerated by healthy adults."( Xanthohumol Microbiome and Signature in Healthy Adults (the XMaS Trial): Safety and Tolerability Results of a Phase I Triple-Masked, Placebo-Controlled Clinical Trial.
Bradley, R; Hanes, D; Langley, BO; Metz, TO; Phipps, J; Ryan, JJ; Stack, E; Stevens, JF, 2021
)
2.33
"Acetaminophen (APAP) is one of the world's popular and safe painkillers, and overdose can cause severe liver damage and even acute liver failure."( Xanthohumol protect against acetaminophen-induced hepatotoxicity via Nrf2 activation through the AMPK/Akt/GSK3β pathway.
Cao, C; Ci, X; Fan, X; Hou, W; Li, K; Zhu, L, 2023
)
2.35

Pharmacokinetics

ExcerptReferenceRelevance
" A single-dose pharmacokinetic (PK) study was conducted in men (n = 24) and women (n = 24) to determine dose-concentration relationships."( Human pharmacokinetics of xanthohumol, an antihyperglycemic flavonoid from hops.
Bobe, G; Choi, J; Christensen, JM; Karnpracha, C; Legette, L; Purnell, JQ; Reed, RL; Rodriguez-Proteau, R; Stevens, JF, 2014
)
0.7
" The mean half-life of XN was 20 h for the 60 and 18 h for the 180 mg dose."( Human pharmacokinetics of xanthohumol, an antihyperglycemic flavonoid from hops.
Bobe, G; Choi, J; Christensen, JM; Karnpracha, C; Legette, L; Purnell, JQ; Reed, RL; Rodriguez-Proteau, R; Stevens, JF, 2014
)
0.7
"To determine pharmacokinetic parameters and bioavailability of pure XN and XN given in prenylflavonoid extract obtained from spent hops (HOP)."( Pharmacokinetics of xanthohumol in rats of both sexes after oral and intravenous administration of pure xanthohumol and prenylflavonoid extract.
Bobak, Ł; Dziewiszek, W; Huszcza, E; Kwiatkowska, J; Matuszewska, A; Nowak, B; Popłoński, J; Poźniak, B; Szeląg, A, 2020
)
0.88
" Although the CMAX concentration was higher in female rats receiving XN orally comparing to males, the other pharmacokinetic parameters were unaffected by the rats' sex."( Pharmacokinetics of xanthohumol in rats of both sexes after oral and intravenous administration of pure xanthohumol and prenylflavonoid extract.
Bobak, Ł; Dziewiszek, W; Huszcza, E; Kwiatkowska, J; Matuszewska, A; Nowak, B; Popłoński, J; Poźniak, B; Szeląg, A, 2020
)
0.88

Bioavailability

The impact of human intestinal bacteria on the bioavailability of the prenylflavonoid xanthohumol (XN) was studied by comparing germ-free (GF) and human microbiota-associated (HMA) rats. XN is present in beer and likely the most consumed prenylated chalcone, but poorly absorbed and rapidly metabolized and excreted.

ExcerptReferenceRelevance
" In session two, rats receive oral administration of 50, 100, 200, 400, and 500 mg/kg body weight XN for bioavailability studies at various dose levels."( High-performance liquid chromatographic determination of xanthohumol in rat plasma, urine, and fecal samples.
Avula, B; Feltenstein, MW; Ganzera, M; Khan, IA; Sufka, KJ; Warnick, JE, 2004
)
0.57
" On the basis of these results radiolabelling of Xn will be performed for in vivo bioavailability studies."( 13C-labelling of xanthohumol in hop cones (Humulus lupulus).
Becker, H; Berwanger, S; Zapp, J, 2005
)
0.67
" Although a number of health effects are attributed to these compounds, only a few reports are available about the bioavailability of prenylflavonoids and the transformation potency of the intestinal microbial community."( Activation of proestrogens from hops (Humulus lupulus L.) by intestinal microbiota; conversion of isoxanthohumol into 8-prenylnaringenin.
De Keukeleire, D; Heyerick, A; Possemiers, S; Robbens, V; Verstraete, W, 2005
)
0.54
" In order to carry out in vivo bioavailability and tissue distribution studies,( 14)C-labelled Xn was produced by biolabelling."( Biosynthetic (14)C-labelling of xanthohumol in hop cones.
Becker, H; Berwanger, S; Frank, N; Knauft, J, 2005
)
0.61
" The uptake, transport and accumulation of xanthohumol were studied using the human intestinal epithelial cell line Caco-2 to help understand the poor bioavailability of this chalcone."( Binding of the hop (Humulus lupulus L.) chalcone xanthohumol to cytosolic proteins in Caco-2 intestinal epithelial cells.
Chadwick, LR; Farnsworth, NR; Nikolic, D; Pang, Y; Pauli, GF; van Breemen, RB; Zhu, D, 2007
)
0.86
"The impact of human intestinal bacteria on the bioavailability of the prenylflavonoid xanthohumol (XN) was studied by comparing germ-free (GF) and human microbiota-associated (HMA) rats."( Recovery and metabolism of xanthohumol in germ-free and human microbiota-associated rats.
Blaut, M; Braune, A; Hanske, L; Loh, G; Sczesny, S, 2010
)
0.88
" Despite many advances in understanding of the pharmacology of XN, one largely unresolved issue is its low bioavailability in the human organism."( Xanthohumol uptake and intracellular kinetics in hepatocytes, hepatic stellate cells, and intestinal cells.
Heilmann, J; Hellerbrand, C; Kraus, B; Motyl, M; Wolff, H, 2011
)
1.81
" Further studies are needed to determine the bioavailability of these compounds and their possible beneficial health effects when taken by moderate beer consumption."( Beer and beer compounds: physiological effects on skin health.
Becker, T; Chen, W; Qian, F; Ring, J, 2014
)
0.4
" This study investigates the interactions between selected prenylflavonoids and breast cancer resistance protein (BCRP/ABCG2), an efflux transporter important for xenobiotic bioavailability and multidrug resistance (MDR)."( Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
Birch, NP; Cooney, J; Jensen, D; Li, Y; Paxton, JW; Scheepens, A; Tan, KW, 2014
)
0.4
" However, poor bioavailability may limit therapeutic applications."( Rice Protein Matrix Enhances Circulating Levels of Xanthohumol Following Acute Oral Intake of Spent Hops in Humans.
Christensen, JM; Contractor, N; Konda, V; O'Connor, A; Reed, RL; Stevens, JF, 2018
)
0.73
" However, poor bioavailability may limit its application in the prevention and therapy of diseases."( Therapeutic Application of Micellar Solubilized Xanthohumol in a Western-Type Diet-Induced Mouse Model of Obesity, Diabetes and Non-Alcoholic Fatty Liver Disease.
Abdel-Tawab, M; Behnam, D; Frank, J; Freese, K; Hellerbrand, C; Mahli, A; Seitz, T; Weiskirchen, R, 2019
)
0.77
" However, low bioavailability and extractive yield limit the clinical applications of XN."( Xanthohumol regulates miR-4749-5p-inhibited RFC2 signaling in enhancing temozolomide cytotoxicity to glioblastoma.
Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Kuo, TC; Lee, CC; Lee, YT; Liu, AJ; Shih, CM, 2020
)
2
"To determine pharmacokinetic parameters and bioavailability of pure XN and XN given in prenylflavonoid extract obtained from spent hops (HOP)."( Pharmacokinetics of xanthohumol in rats of both sexes after oral and intravenous administration of pure xanthohumol and prenylflavonoid extract.
Bobak, Ł; Dziewiszek, W; Huszcza, E; Kwiatkowska, J; Matuszewska, A; Nowak, B; Popłoński, J; Poźniak, B; Szeląg, A, 2020
)
0.88
" The formulation-dependent factors also play an important role in the bioavailability of the drug."( Pharmacokinetics of xanthohumol in rats of both sexes after oral and intravenous administration of pure xanthohumol and prenylflavonoid extract.
Bobak, Ł; Dziewiszek, W; Huszcza, E; Kwiatkowska, J; Matuszewska, A; Nowak, B; Popłoński, J; Poźniak, B; Szeląg, A, 2020
)
0.88
" Xanthohumol is present in beer and likely the most consumed prenylated chalcone, but poorly absorbed and rapidly metabolized and excreted, thus limiting its bioavailability."( The Pharmacokinetics of Individual Conjugated Xanthohumol Metabolites Show Efficient Glucuronidation and Higher Bioavailability of Micellar than Native Xanthohumol in a Randomized, Double-Blind, Crossover Trial in Healthy Humans.
Buckett, L; Frank, J; Rychlik, M; Schoergenhofer, C; Spindler, V; Sus, N, 2023
)
2.08
" The oral bioavailability of micellar xanthohumol is superior to native xanthohumol, making it a useful delivery form for future human trials."( The Pharmacokinetics of Individual Conjugated Xanthohumol Metabolites Show Efficient Glucuronidation and Higher Bioavailability of Micellar than Native Xanthohumol in a Randomized, Double-Blind, Crossover Trial in Healthy Humans.
Buckett, L; Frank, J; Rychlik, M; Schoergenhofer, C; Spindler, V; Sus, N, 2023
)
1.44

Dosage Studied

ExcerptRelevanceReference
" The use of XN-enriched hop products combined with a late hop dosage during wort boiling proved to be effective in increasing the XN content in beer."( Enrichment of xanthohumol in the brewing process.
Back, W; Wunderlich, S; Zürcher, A, 2005
)
0.69
" A five-fold increase in the dosage of IX without change in 8-PN concentration resulted in a significant lower IX recovery and a higher 8-PN recovery."( Microbial and dietary factors associated with the 8-prenylnaringenin producer phenotype: a dietary intervention trial with fifty healthy post-menopausal Caucasian women.
Bolca, S; Bracke, M; De Henauw, S; De Keukeleire, D; Depypere, H; Heyerick, A; Huybrechts, I; Maervoet, V; Possemiers, S; Van de Wiele, T; Verstraete, W; Vervarcke, S, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antiviral agentA substance that destroys or inhibits replication of viruses.
EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitorAn EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor that interferes with the action of diacylglycerol O-acyltransferase (EC 2.3.1.20).
anti-HIV-1 agentAn anti-HIV agent that destroys or inhibits the replication of HIV-1, the more infective and more virulent of the two types of HIV virus.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
chalconesA ketone that is 1,3-diphenylpropenone (benzylideneacetophenone), ArCH=CH(=O)Ar, and its derivatives formed by substitution.
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)IC50 (µMol)6.60000.00251.45139.0000AID663997
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)2.50000.00011.68479.3200AID1304625; AID1304628
Protein kinase C alpha typeHomo sapiens (human)IC50 (µMol)100.00000.00010.972010.0000AID663998
Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)IC50 (µMol)30.00000.00011.97318.0000AID1762748
Nuclear factor NF-kappa-B p100 subunit Homo sapiens (human)IC50 (µMol)30.00000.00011.80888.0000AID1762748
Transcription factor p65Homo sapiens (human)IC50 (µMol)30.00000.00011.89818.8000AID1762748
Protein kinase C theta typeHomo sapiens (human)IC50 (µMol)100.00000.00010.989710.0000AID663999
Thioredoxin reductase 1, cytoplasmicHomo sapiens (human)IC50 (µMol)40.00000.04322.26555.0000AID1199613
Thioredoxin reductase 3Homo sapiens (human)IC50 (µMol)40.00000.35003.11675.0000AID1199613
Thioredoxin reductase 2, mitochondrialHomo sapiens (human)IC50 (µMol)40.00000.35003.11675.0000AID1199613
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TransthyretinHomo sapiens (human)Kd12.00000.00301.348210.0000AID1705465
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NAD(P)H dehydrogenase [quinone] 1Mus musculus (house mouse)CD1.30000.00020.23892.6500AID1379242
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (223)

Processvia Protein(s)Taxonomy
intracellular signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
type B pancreatic cell development3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of protein kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
hyperosmotic response3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
epidermal growth factor receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
insulin receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of phospholipase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic process3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cell migration3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
calcium-mediated signaling3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
actin cytoskeleton organization3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
T cell costimulation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
activation of protein kinase B activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cellular response to insulin stimulus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of toll-like receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
regulation of canonical NF-kappaB signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
regulation of mast cell degranulation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of angiogenesis3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein autophosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cellular response to epidermal growth factor stimulus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of protein localization to plasma membrane3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of sprouting angiogenesis3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of endothelial cell apoptotic process3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
intracellular signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell proliferationProtein kinase C alpha typeHomo sapiens (human)
desmosome assemblyProtein kinase C alpha typeHomo sapiens (human)
chromatin remodelingProtein kinase C alpha typeHomo sapiens (human)
protein phosphorylationProtein kinase C alpha typeHomo sapiens (human)
mitotic nuclear membrane disassemblyProtein kinase C alpha typeHomo sapiens (human)
cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyProtein kinase C alpha typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C alpha typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C alpha typeHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
post-translational protein modificationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of macrophage differentiationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of bone resorptionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of mitotic cell cycleProtein kinase C alpha typeHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein kinase C alpha typeHomo sapiens (human)
response to interleukin-1Protein kinase C alpha typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C alpha typeHomo sapiens (human)
apoptotic signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiotensin-activated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of dense core granule biogenesisProtein kinase C alpha typeHomo sapiens (human)
intracellular signal transductionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C alpha typeHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to lipopolysaccharideNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
JNK cascadeNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of gene expressionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of lipid storageNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of calcidiol 1-monooxygenase activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of vitamin D biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of cholesterol transportNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of interleukin-12 productionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to muscle stretchNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
B cell receptor signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of protein metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mammary gland involutionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription initiation by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to mechanical stimulusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to nicotineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-1Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-6Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to tumor necrosis factorNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to dsRNANuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-17Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to virusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
antibacterial innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of hyaluronan biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to angiotensinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of miRNA metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
follicular dendritic cell differentiationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
germinal center formationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
extracellular matrix organizationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
response to lipopolysaccharideNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
rhythmic processNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
spleen developmentNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
positive regulation of interleukin-1 beta productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
positive regulation of amyloid-beta formationTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
liver developmentTranscription factor p65Homo sapiens (human)
hair follicle developmentTranscription factor p65Homo sapiens (human)
defense response to tumor cellTranscription factor p65Homo sapiens (human)
response to ischemiaTranscription factor p65Homo sapiens (human)
acetaldehyde metabolic processTranscription factor p65Homo sapiens (human)
chromatin organizationTranscription factor p65Homo sapiens (human)
DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
inflammatory responseTranscription factor p65Homo sapiens (human)
cellular defense responseTranscription factor p65Homo sapiens (human)
neuropeptide signaling pathwayTranscription factor p65Homo sapiens (human)
canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of cell population proliferationTranscription factor p65Homo sapiens (human)
response to xenobiotic stimulusTranscription factor p65Homo sapiens (human)
animal organ morphogenesisTranscription factor p65Homo sapiens (human)
response to UV-BTranscription factor p65Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionTranscription factor p65Homo sapiens (human)
positive regulation of gene expressionTranscription factor p65Homo sapiens (human)
positive regulation of Schwann cell differentiationTranscription factor p65Homo sapiens (human)
negative regulation of angiogenesisTranscription factor p65Homo sapiens (human)
cytokine-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
protein catabolic processTranscription factor p65Homo sapiens (human)
response to muramyl dipeptideTranscription factor p65Homo sapiens (human)
response to progesteroneTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-12 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
response to insulinTranscription factor p65Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein sumoylationTranscription factor p65Homo sapiens (human)
response to cobalaminTranscription factor p65Homo sapiens (human)
toll-like receptor 4 signaling pathwayTranscription factor p65Homo sapiens (human)
intracellular signal transductionTranscription factor p65Homo sapiens (human)
cellular response to hepatocyte growth factor stimulusTranscription factor p65Homo sapiens (human)
response to muscle stretchTranscription factor p65Homo sapiens (human)
non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
vascular endothelial growth factor signaling pathwayTranscription factor p65Homo sapiens (human)
prolactin signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein catabolic processTranscription factor p65Homo sapiens (human)
negative regulation of apoptotic processTranscription factor p65Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
response to amino acidTranscription factor p65Homo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTranscription factor p65Homo sapiens (human)
regulation of inflammatory responseTranscription factor p65Homo sapiens (human)
positive regulation of T cell receptor signaling pathwayTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
response to cAMPTranscription factor p65Homo sapiens (human)
defense response to virusTranscription factor p65Homo sapiens (human)
cellular response to hydrogen peroxideTranscription factor p65Homo sapiens (human)
interleukin-1-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to lipopolysaccharideTranscription factor p65Homo sapiens (human)
cellular response to lipoteichoic acidTranscription factor p65Homo sapiens (human)
cellular response to peptidoglycanTranscription factor p65Homo sapiens (human)
cellular response to nicotineTranscription factor p65Homo sapiens (human)
cellular response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to interleukin-6Transcription factor p65Homo sapiens (human)
cellular response to tumor necrosis factorTranscription factor p65Homo sapiens (human)
postsynapse to nucleus signaling pathwayTranscription factor p65Homo sapiens (human)
antiviral innate immune responseTranscription factor p65Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
negative regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
cellular response to angiotensinTranscription factor p65Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTranscription factor p65Homo sapiens (human)
positive regulation of miRNA metabolic processTranscription factor p65Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTranscription factor p65Homo sapiens (human)
cellular response to stressTranscription factor p65Homo sapiens (human)
response to cytokineTranscription factor p65Homo sapiens (human)
innate immune responseTranscription factor p65Homo sapiens (human)
regulation of cell growthProtein kinase C theta typeHomo sapiens (human)
regulation of DNA-templated transcriptionProtein kinase C theta typeHomo sapiens (human)
protein phosphorylationProtein kinase C theta typeHomo sapiens (human)
membrane protein ectodomain proteolysisProtein kinase C theta typeHomo sapiens (human)
inflammatory responseProtein kinase C theta typeHomo sapiens (human)
axon guidanceProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-17 productionProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-2 productionProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-4 productionProtein kinase C theta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C theta typeHomo sapiens (human)
CD4-positive, alpha-beta T cell proliferationProtein kinase C theta typeHomo sapiens (human)
Fc-epsilon receptor signaling pathwayProtein kinase C theta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C theta typeHomo sapiens (human)
positive regulation of T cell activationProtein kinase C theta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomerase activityProtein kinase C theta typeHomo sapiens (human)
cell chemotaxisProtein kinase C theta typeHomo sapiens (human)
negative regulation of T cell apoptotic processProtein kinase C theta typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomere cappingProtein kinase C theta typeHomo sapiens (human)
positive regulation of T-helper 17 type immune responseProtein kinase C theta typeHomo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferationProtein kinase C theta typeHomo sapiens (human)
positive regulation of T-helper 2 cell activationProtein kinase C theta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C theta typeHomo sapiens (human)
mesoderm formationThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
signal transductionThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cell population proliferationThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cellular oxidant detoxificationThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cell redox homeostasisThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
spermatogenesisThioredoxin reductase 3Homo sapiens (human)
cell differentiationThioredoxin reductase 3Homo sapiens (human)
cell redox homeostasisThioredoxin reductase 3Homo sapiens (human)
cellular oxidant detoxificationThioredoxin reductase 3Homo sapiens (human)
response to oxygen radicalThioredoxin reductase 2, mitochondrialHomo sapiens (human)
response to xenobiotic stimulusThioredoxin reductase 2, mitochondrialHomo sapiens (human)
response to selenium ionThioredoxin reductase 2, mitochondrialHomo sapiens (human)
cell redox homeostasisThioredoxin reductase 2, mitochondrialHomo sapiens (human)
response to hyperoxiaThioredoxin reductase 2, mitochondrialHomo sapiens (human)
cellular oxidant detoxificationThioredoxin reductase 2, mitochondrialHomo sapiens (human)
response to lipopolysaccharideLymphocyte antigen 96Homo sapiens (human)
toll-like receptor signaling pathwayLymphocyte antigen 96Homo sapiens (human)
inflammatory responseLymphocyte antigen 96Homo sapiens (human)
cellular defense responseLymphocyte antigen 96Homo sapiens (human)
cell surface receptor signaling pathwayLymphocyte antigen 96Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayLymphocyte antigen 96Homo sapiens (human)
response to lipopolysaccharideLymphocyte antigen 96Homo sapiens (human)
detection of lipopolysaccharideLymphocyte antigen 96Homo sapiens (human)
positive regulation of tumor necrosis factor productionLymphocyte antigen 96Homo sapiens (human)
toll-like receptor 4 signaling pathwayLymphocyte antigen 96Homo sapiens (human)
innate immune responseLymphocyte antigen 96Homo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayLymphocyte antigen 96Homo sapiens (human)
cellular response to lipopolysaccharideLymphocyte antigen 96Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (58)

Processvia Protein(s)Taxonomy
protein serine/threonine kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
3-phosphoinositide-dependent protein kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
ATP binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
phospholipase activator activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
phospholipase binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein serine kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
integrin bindingProtein kinase C alpha typeHomo sapiens (human)
protein bindingProtein kinase C alpha typeHomo sapiens (human)
ATP bindingProtein kinase C alpha typeHomo sapiens (human)
zinc ion bindingProtein kinase C alpha typeHomo sapiens (human)
enzyme bindingProtein kinase C alpha typeHomo sapiens (human)
histone H3T6 kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol bindingProtein kinase C alpha typeHomo sapiens (human)
transcription cis-regulatory region bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription coregulator activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
identical protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
actinin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
protein bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
transcription cis-regulatory region bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
transcription coactivator bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA bindingTranscription factor p65Homo sapiens (human)
chromatin bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activityTranscription factor p65Homo sapiens (human)
protein bindingTranscription factor p65Homo sapiens (human)
enzyme bindingTranscription factor p65Homo sapiens (human)
protein kinase bindingTranscription factor p65Homo sapiens (human)
chromatin DNA bindingTranscription factor p65Homo sapiens (human)
ubiquitin protein ligase bindingTranscription factor p65Homo sapiens (human)
peptide bindingTranscription factor p65Homo sapiens (human)
phosphate ion bindingTranscription factor p65Homo sapiens (human)
identical protein bindingTranscription factor p65Homo sapiens (human)
protein homodimerization activityTranscription factor p65Homo sapiens (human)
actinin bindingTranscription factor p65Homo sapiens (human)
histone deacetylase bindingTranscription factor p65Homo sapiens (human)
NF-kappaB bindingTranscription factor p65Homo sapiens (human)
ankyrin repeat bindingTranscription factor p65Homo sapiens (human)
general transcription initiation factor bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor bindingTranscription factor p65Homo sapiens (human)
protein kinase activityProtein kinase C theta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C theta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C theta typeHomo sapiens (human)
protein bindingProtein kinase C theta typeHomo sapiens (human)
ATP bindingProtein kinase C theta typeHomo sapiens (human)
metal ion bindingProtein kinase C theta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C theta typeHomo sapiens (human)
thioredoxin-disulfide reductase (NADPH) activityThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
protein bindingThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
identical protein bindingThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
NADPH peroxidase activityThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
FAD bindingThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
thioredoxin-disulfide reductase (NADPH) activityThioredoxin reductase 3Homo sapiens (human)
flavin adenine dinucleotide bindingThioredoxin reductase 3Homo sapiens (human)
thioredoxin-disulfide reductase (NADPH) activityThioredoxin reductase 2, mitochondrialHomo sapiens (human)
protein bindingThioredoxin reductase 2, mitochondrialHomo sapiens (human)
protein homodimerization activityThioredoxin reductase 2, mitochondrialHomo sapiens (human)
protein-containing complex bindingThioredoxin reductase 2, mitochondrialHomo sapiens (human)
flavin adenine dinucleotide bindingThioredoxin reductase 2, mitochondrialHomo sapiens (human)
lipopolysaccharide bindingLymphocyte antigen 96Homo sapiens (human)
lipopolysaccharide immune receptor activityLymphocyte antigen 96Homo sapiens (human)
protein bindingLymphocyte antigen 96Homo sapiens (human)
coreceptor activityLymphocyte antigen 96Homo sapiens (human)
Toll-like receptor 4 bindingLymphocyte antigen 96Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (45)

Processvia Protein(s)Taxonomy
nucleus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasm3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytosol3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
plasma membrane3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
focal adhesion3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
postsynaptic density3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasmic vesicle3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cell projection3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ciliary basal bodyProtein kinase C alpha typeHomo sapiens (human)
nucleoplasmProtein kinase C alpha typeHomo sapiens (human)
cytoplasmProtein kinase C alpha typeHomo sapiens (human)
mitochondrionProtein kinase C alpha typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C alpha typeHomo sapiens (human)
cytosolProtein kinase C alpha typeHomo sapiens (human)
plasma membraneProtein kinase C alpha typeHomo sapiens (human)
mitochondrial membraneProtein kinase C alpha typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C alpha typeHomo sapiens (human)
extracellular exosomeProtein kinase C alpha typeHomo sapiens (human)
alphav-beta3 integrin-PKCalpha complexProtein kinase C alpha typeHomo sapiens (human)
extracellular regionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mitochondrionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytosolNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
secretory granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
specific granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription regulator complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
I-kappaB/NF-kappaB complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
NF-kappaB p50/p65 complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytosolNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
chromatinNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
Bcl3/NF-kappaB2 complexNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleusNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleolusTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
glutamatergic synapseTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
nucleoplasmTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
cytosolTranscription factor p65Homo sapiens (human)
NF-kappaB p50/p65 complexTranscription factor p65Homo sapiens (human)
NF-kappaB complexTranscription factor p65Homo sapiens (human)
chromatinTranscription factor p65Homo sapiens (human)
transcription regulator complexTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
immunological synapseProtein kinase C theta typeHomo sapiens (human)
cytosolProtein kinase C theta typeHomo sapiens (human)
plasma membraneProtein kinase C theta typeHomo sapiens (human)
aggresomeProtein kinase C theta typeHomo sapiens (human)
centriolar satelliteProtein kinase C theta typeHomo sapiens (human)
fibrillar centerThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
nucleoplasmThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cytosolThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
extracellular exosomeThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
mitochondrionThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cytosolThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cytoplasmThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
nucleoplasmThioredoxin reductase 3Homo sapiens (human)
endoplasmic reticulumThioredoxin reductase 3Homo sapiens (human)
cytosolThioredoxin reductase 3Homo sapiens (human)
mitochondrionThioredoxin reductase 3Homo sapiens (human)
cytoplasmThioredoxin reductase 3Homo sapiens (human)
cytosolThioredoxin reductase 3Homo sapiens (human)
mitochondrionThioredoxin reductase 2, mitochondrialHomo sapiens (human)
mitochondrial matrixThioredoxin reductase 2, mitochondrialHomo sapiens (human)
cytosolThioredoxin reductase 2, mitochondrialHomo sapiens (human)
axonThioredoxin reductase 2, mitochondrialHomo sapiens (human)
dendriteThioredoxin reductase 2, mitochondrialHomo sapiens (human)
neuronal cell bodyThioredoxin reductase 2, mitochondrialHomo sapiens (human)
cytoplasmThioredoxin reductase 2, mitochondrialHomo sapiens (human)
mitochondrionThioredoxin reductase 2, mitochondrialHomo sapiens (human)
cytosolThioredoxin reductase 2, mitochondrialHomo sapiens (human)
extracellular regionLymphocyte antigen 96Homo sapiens (human)
plasma membraneLymphocyte antigen 96Homo sapiens (human)
endosome membraneLymphocyte antigen 96Homo sapiens (human)
receptor complexLymphocyte antigen 96Homo sapiens (human)
lipopolysaccharide receptor complexLymphocyte antigen 96Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (167)

Assay IDTitleYearJournalArticle
AID638297Induction of apoptosis in human U87MG cells at 50 uM after 48 hrs by propidium iodide staining based flow cytometric analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1378635Antimigratory activity in HUVEC at 10 uM after 6 hrs by DAPI staining based Boyden chamber method2017European journal of medicinal chemistry, Sep-29, Volume: 138Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues.
AID663999Inhibition of human PKC theta assessed as inhibition of [33P] incorporation into substrate after 60 mins by scintillation counting2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Inverse Virtual Screening allows the discovery of the biological activity of natural compounds.
AID1058189Antioxidant activity in streptozotocin-induced diabetic Wistar rat model assessed as increase in reduced glutathione level in serum at 10 mg/L, po administered with superbock stout beer for 5 weeks prior to wounding measured on day 7 post-wounding by RP-H2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing.
AID638294Induction of cell cycle arrest in human U87MG cells assessed as accumulation at S phase at 1 to 20 uM after 48 hrs by flow cytometric analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1378630Cytotoxicity against HUVEC assessed as reduction in cell viability at 20 uM up to 96 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues.
AID1058188Antioxidant activity in streptozotocin-induced diabetic Wistar rat model assessed as increase in H2O2 release in liver at 10 mg/L, po administered with superbock stout beer for 5 weeks prior to wounding measured on day 7 post-wounding by fluorescence assa2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing.
AID310856Inhibition of HIV1 reverse transcriptase production in human C8166 lymphocytes2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
A review of anti-infective and anti-inflammatory chalcones.
AID1379242Induction of NQO1 activity in mouse Hepa1c1c7 cells after 48 hrs by MTT reduction assay2017Journal of natural products, 08-25, Volume: 80, Issue:8
DESIGNER Extracts as Tools to Balance Estrogenic and Chemopreventive Activities of Botanicals for Women's Health.
AID734217Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Fungal metabolites of xanthohumol with potent antiproliferative activity on human cancer cell lines in vitro.
AID468367Antioxidant activity in human HEK293 cells loaded with dihyfrofluresceindiacetate at 1 mM2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID1667214Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 25 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID638288Cytotoxicity against normal human astrocytes assessed as decrease in cell viability after 48 hrs by MTT assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID638388Induction of apoptosis in human T98G cells assessed as caspase activation at 20 uM after 24 hrs pretreated with 25 uM pancaspase inhibitor Z-VAD-FMK2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1058187Antioxidant activity in streptozotocin-induced diabetic Wistar rat model assessed as reduction in 3-NT protein expression in liver at 10 mg/L, po administered with superbock stout beer for 5 weeks prior to wounding measured on day 7 post-wounding by Weste2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing.
AID468361Inhibition of AKt phosphorylation in Sprague-Dawley rat ischemic reperfusion treated hepatic tissue at 2.26 mM before ischemic period by Western blot analysis2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID1423944Stimulation of growth in human Caco2 cells assessed as reduction in ATP metabolism at 10 uM incubated for 24 hrs by cell-titer-Glo luminescent cell viability assay2017Journal of natural products, 04-28, Volume: 80, Issue:4
Effect of Hops Derived Prenylated Phenols on TNF-α Induced Barrier Dysfunction in Intestinal Epithelial Cells.
AID1774070Neuro-regenerative activity in NMRI mouse MEF cells transfected with human DCX promoter-driven firefly luciferase reporter assessed as induction of neuronal differentiation at 10 uM incubated for 3 days by luciferase reporter gene based luminescence analy2021Journal of natural products, 10-22, Volume: 84, Issue:10
Neuroregenerative Potential of Prenyl- and Pyranochalcones: A Structure-Activity Study.
AID663998Inhibition of human PKC alpha assessed as inhibition of [33P] incorporation into substrate after 60 mins by scintillation counting2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Inverse Virtual Screening allows the discovery of the biological activity of natural compounds.
AID1417244Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis, and evaluation of chalcone analogues incorporate α,β-Unsaturated ketone functionality as anti-lung cancer agents via evoking ROS to induce pyroptosis.
AID468355Cytotoxicity against human HEK293 cells upto 10 to 300 uM after 3 hrs by MTT assay2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID468362Reduction of Bcl-xl level in Sprague-Dawley rat ischemic-reperfused hepatic tissue at 2.26 mM treated before ischemic period by Western blot analysis2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID1199613Inhibition of TrxR in human HeLa cells assessed as depletion of cellular thiol after 48 hrs2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Synthesis of xanthohumol analogues and discovery of potent thioredoxin reductase inhibitor as potential anticancer agent.
AID1403214Anti-growth activity against human NCI-H460 cells assessed as reduction in colony formation at 10 uM after 48 hrs by crystal violet-based colony forming assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and QSAR study of novel isatin analogues inspired Michael acceptor as potential anticancer compounds.
AID638287Anticancer activity against human U87MG cells assessed as decrease in cell viability at 50 uM after 48 hrs by MTT assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID638397Induction of apoptosis in human T98G cells assessed as decrease in Bcl-2 expression at 20 uM after 48 hrs by Western blot analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1378634Antiangiogenic activity in fibronectin pretreated HUVEC assessed as reduction in cell adhesion at 10 uM after 90 mins by DAPI staining based microscopic method2017European journal of medicinal chemistry, Sep-29, Volume: 138Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues.
AID1377244Inhibition of PDGF-BB-induced rat VSMC proliferation preincubated for 30 mins followed by PDGF-BB addition measured after 48 hrs by resazurin assay2017Journal of natural products, 07-28, Volume: 80, Issue:7
Xanthohumol Blocks Proliferation and Migration of Vascular Smooth Muscle Cells in Vitro and Reduces Neointima Formation in Vivo.
AID1254735Terminal half life in human at 60 mg, po by LC-MS/MS method2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Development of Safe and Effective Botanical Dietary Supplements.
AID638466Anticancer activity against human T98G cells assessed as decrease in cell viability at 20 uM after 48 hrs by MTT assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1199602Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Synthesis of xanthohumol analogues and discovery of potent thioredoxin reductase inhibitor as potential anticancer agent.
AID1087277Antiproliferative activity against Homo sapiens (human) CCRF-CEM cells after 72 hr by MTT assay2012Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, Dec, Volume: 21, Issue:12
Antiproliferative activity and synthesis of 8-prenylnaringenin derivatives by demethylation of 7-O- and 4'-O-substituted isoxanthohumols.
AID638459Induction of p38 phosphorylation in human T98G cells at 20 uM after 30 to 60 mins for 2 hrs by Western blot analysis in presence of 5 mM NAC2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1423948Inhibition of TNFalpha induced barrier dysfunctionin human Caco2 cells assessed as increase in transepithelial electrical resistance at 10 uM treated on apical side for 1 hr post TNFalpha stimulation on basolateral side for 24 hrs and measured after 72 hr2017Journal of natural products, 04-28, Volume: 80, Issue:4
Effect of Hops Derived Prenylated Phenols on TNF-α Induced Barrier Dysfunction in Intestinal Epithelial Cells.
AID638295Induction of apoptosis in human T98G cells assessed as increase in subG1 population after 24 to 48 hrs by propidium iodide staining based flow cytometric analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID638396Induction of apoptosis in human T98G cells assessed as decrease in Bcl-2 expression at 20 uM by Western blot analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID468359Inhibition of TNF alpha-induced NF-kappaB binding activity in Sprague-Dawley rat liver at 2.26 mM treated prior to ischemic reperfusion by EMSA2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID1504720Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay2017Journal of natural products, 12-22, Volume: 80, Issue:12
Characteristic α-Acid Derivatives from Humulus lupulus with Antineuroinflammatory Activities.
AID638455Induction of Erk1/2 phosphorylation in human T98G cells at 20 uM measured every 5 mins for 2 hrs by Western blot analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1199603Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Synthesis of xanthohumol analogues and discovery of potent thioredoxin reductase inhibitor as potential anticancer agent.
AID638289Induction of cell cycle arrest in human T98G cells assessed as accumulation at G0/G1 phase at 1 to 20 uM after 48 hrs by flow cytometric analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID638395Induction of apoptosis in human T98G cells assessed as increase in cytosolic cytochrome c release at 20 uM after 8 hrs by Western blot analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1423947Inhibition of TNFalpha induced barrier dysfunctionin human Caco2 cells assessed as increase in transepithelial electrical resistance at 10 uM pre-treated on apical side for 1 hr before TNFalpha stimulation on basolateral side for 72 hrs by cellZScope moni2017Journal of natural products, 04-28, Volume: 80, Issue:4
Effect of Hops Derived Prenylated Phenols on TNF-α Induced Barrier Dysfunction in Intestinal Epithelial Cells.
AID486192Antioxidant activity assessed as trolox equivalents of AAPH radical scavenging activity after 15 mins by ORAC-fluorescein assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis, cytotoxicity, anti-oxidative and anti-inflammatory activity of chalcones and influence of A-ring modifications on the pharmacological effect.
AID1762748Inhibition of TNFalpha-induced NFkappaB activation in HEK293 cells assessed as luciferase expression by luciferase reporter activity assay2021Bioorganic & medicinal chemistry letters, 06-15, Volume: 42Synthesis of pyranochalcone derivatives and their inhibitory effect on NF-κB activation.
AID1604244Cytotoxicity against human DU145 cells assessed as reduction in cell viability relative to control2019European journal of medicinal chemistry, Dec-01, Volume: 183Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins.
AID638468Toxicity in mouse2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID638458Induction of Erk1/2 phosphorylation in human T98G cells at 20 uM measured every 5 mins for 2 hrs by Western blot analysis in presence of 5 mM of NAC2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID638291Induction of cell cycle arrest in human T98G cells assessed as accumulation at S phase at 1 to 20 uM after 48 hrs by flow cytometric analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1604245Cytotoxicity against human MCF7 cells assessed as reduction in cell viability at 0.01 uM after 48 hrs by fluorescence assay relative to control2019European journal of medicinal chemistry, Dec-01, Volume: 183Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins.
AID638394Induction of apoptosis in human T98G cells assessed as increase in mitochondrial depolarization at 20 uM after 24 hrs by TREM fluorescence analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1379240Estrogenic activity at estrogen receptor alpha in human Ishikawa cells assessed as induction of alkaline phosphatase activity using p-Nitrophenol phosphate as substrate pretreated for 96 hrs followed by substrate addition measured every 15 secs by scannin2017Journal of natural products, 08-25, Volume: 80, Issue:8
DESIGNER Extracts as Tools to Balance Estrogenic and Chemopreventive Activities of Botanicals for Women's Health.
AID486191Cytotoxicity against human HeLa cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis, cytotoxicity, anti-oxidative and anti-inflammatory activity of chalcones and influence of A-ring modifications on the pharmacological effect.
AID1058185Antioxidant activity in streptozotocin-induced diabetic Wistar rat model assessed as reduction in protein carbonylation in kidney at 10 mg/L, po administered with superbock stout beer for 5 weeks prior to wounding measured on day 7 post-wounding by Wester2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing.
AID638292Induction of cell cycle arrest in human U87MG cells assessed as accumulation at G0/G1 phase at 1 to 20 uM after 48 hrs by flow cytometric analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID486193Antiinflammatory activity in human HMEC1 cells assessed as inhibition of TNF-alpha-induced ICAM-1 expression at 10 uM after 24 hrs by FACS analysis2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis, cytotoxicity, anti-oxidative and anti-inflammatory activity of chalcones and influence of A-ring modifications on the pharmacological effect.
AID468366Effect on ischemic and reperfusion-induced injury in Sprague-Dawley rat hepatic tissue at 2.26 mM before ischemic period assessed as LDH level2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID1604246Cytotoxicity against human MCF7 cells assessed as reduction in cell viability at 5 uM after 48 hrs by fluorescence assay relative to control2019European journal of medicinal chemistry, Dec-01, Volume: 183Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins.
AID340662Antioxidant activity assessed as trolox equivalents at 0.1 to 1 uM by ORAC-fluorescein assay2008Journal of natural products, Jul, Volume: 71, Issue:7
Synthesis, cytotoxicity, and antioxidative activity of minor prenylated chalcones from Humulus lupulus.
AID1058193Antiinflammatory activity in streptozotocin-induced diabetic Wistar rat model assessed as reduction in IL1beta level in serum at 10 mg/L, po administered with superbock stout beer for 5 weeks prior to wounding measured on day 7 post-wounding by ELISA (Rvb2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing.
AID638403Induction of apoptosis in human T98G cells assessed as increase in ROS production at 20 uM after 48 hrs by DCFH-DA staining-based flow cytometric analysis in presence of 10 uM ascorbic acid2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID340661Cytotoxicity against human HeLa cells by MTT assay after 72 hrs2008Journal of natural products, Jul, Volume: 71, Issue:7
Synthesis, cytotoxicity, and antioxidative activity of minor prenylated chalcones from Humulus lupulus.
AID638457Induction of JNK phosphorylation in human T98G cells at 20 uM after 30 to 60 mins for 2 hrs by Western blot analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID468358Inhibition of ischemic and reperfusion-induced oxidative stress in Sprague-Dawley rat hepatic tissue at 26.6 mM before ischemic period assessed as decrease in 8-isoprostane level2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID1058197Antioxidant activity in streptozotocin-induced diabetic Wistar rat model assessed as decrease in H2O2 release in kidney at 10 mg/L, po administered with superbock stout beer for 5 weeks prior to wounding measured on day 7 post-wounding by fluorescence ass2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing.
AID1604241Cytotoxicity against human LNCAP cells assessed as reduction in cell viability relative to control2019European journal of medicinal chemistry, Dec-01, Volume: 183Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins.
AID310855Inhibition of HIV1 p24 antigen production in human C8166 lymphocytes2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
A review of anti-infective and anti-inflammatory chalcones.
AID638286Anticancer activity against human T98G cells assessed as decrease in cell viability at 50 uM after 48 hrs by MTT assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID738109Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Antioxidant and antiproliferative activity of glycosides obtained by biotransformation of xanthohumol.
AID1403210Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and QSAR study of novel isatin analogues inspired Michael acceptor as potential anticancer compounds.
AID638406Induction of apoptosis in human T98G cells assessed as cleavage PARP protein level at 20 uM after 24 hrs by Western blot analysis in presence of 5 mM NAC2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1377247Inhibition of cuff-induced restenosis in C57BL/6 mouse femoral artery cuff model assessed as reduction in neointima formation dosed via local application using compound dissolved on F-127 gel measured after 2 weeks by hematoxylin and eosin staining-based 2017Journal of natural products, 07-28, Volume: 80, Issue:7
Xanthohumol Blocks Proliferation and Migration of Vascular Smooth Muscle Cells in Vitro and Reduces Neointima Formation in Vivo.
AID376753Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at <10 uM after 16 hrs by MTT assay2005Journal of natural products, Jan, Volume: 68, Issue:1
Prenylflavonoids and phloroglucinol derivatives from hops (Humulus lupulus).
AID468356Inhibition of ischemic and reperfusion-induced of GSH activity in Sprague-Dawley rat hepatic tissue at 26.6 mM before ischemic period by DTNB reduction assay2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID638402Induction of apoptosis in human T98G cells assessed as increase in ROS production at 20 uM after 48 hrs by DCFH-DA staining-based flow cytometric analysis in presence of 5 mM NAC2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1501516Displacement of bis-ANS from recombinant human MD2 at 10 uM after 5 mins by fluorescence assay relative to control2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of new MD2-targeted anti-inflammatory compounds for the treatment of sepsis and acute lung injury.
AID1304625Inhibition of recombinant human 5-LO expressed in Escherichia coli MV1190 cells preincubated for 10 mins followed by addition of arachidonic acid as substrate measured after 10 mins by RP-HPLC method2016Journal of natural products, Mar-25, Volume: 79, Issue:3
Humudifucol and Bioactive Prenylated Polyphenols from Hops (Humulus lupulus cv. "Cascade").
AID1197888Non-competitive inhibition of alpha-glucosidase (unknown origin)2015European journal of medicinal chemistry, Mar-06, Volume: 92Chalcones and their therapeutic targets for the management of diabetes: structural and pharmacological perspectives.
AID310857Antiviral activity against HIV1 3B assessed as inhibition of p24 antigen production in human PBMCs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
A review of anti-infective and anti-inflammatory chalcones.
AID638390Induction of apoptosis in human T98G cells assessed as increase in caspase-9 expression level at 20 uM after 8 hrs by Western blot analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID638462Induction of p38 phosphorylation in human T98G cells at 20 uM measured after 24 hrs by Western blot analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID638293Induction of cell cycle arrest in human U87MG cells assessed as accumulation at G2/M phase at 1 to 20 uM after 48 hrs by flow cytometric analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1379241Cytotoxicity against human Ishikawa cells after 96 hrs by SRB assay2017Journal of natural products, 08-25, Volume: 80, Issue:8
DESIGNER Extracts as Tools to Balance Estrogenic and Chemopreventive Activities of Botanicals for Women's Health.
AID1058192Antiinflammatory activity in streptozotocin-induced diabetic Wistar rat model assessed as reduction in N-acetylglucosaminidase level in serum at 10 mg/L, po administered with superbock stout beer for 5 weeks prior to wounding measured on day 7 post-woundi2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing.
AID638460Induction of Erk1/2 phosphorylation in human T98G cells at 20 uM measured after 24 hrs by Western blot analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1604243Cytotoxicity against human PC3 cells assessed as reduction in cell viability relative to control2019European journal of medicinal chemistry, Dec-01, Volume: 183Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins.
AID1304628Inhibition of 5-LO in human polymorphonuclear leukocytes preincubated for 10 mins followed by addition of arachidonic acid as substrate measured after 10 mins by HPLC method2016Journal of natural products, Mar-25, Volume: 79, Issue:3
Humudifucol and Bioactive Prenylated Polyphenols from Hops (Humulus lupulus cv. "Cascade").
AID1604242Cytotoxicity against human C4-2 cells assessed as reduction in cell viability relative to control2019European journal of medicinal chemistry, Dec-01, Volume: 183Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins.
AID468365Effect on ischemic and reperfusion-induced injury in Sprague-Dawley rat hepatic tissue at 2.26 mM before ischemic period assessed as AST level2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID468354Antioxidant activity in human HEK293 cells loaded with dihyfrofluresceindiacetate at 40 uM2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID638290Induction of cell cycle arrest in human T98G cells assessed as accumulation at G2/M phase at 1 to 20 uM after 48 hrs by flow cytometric analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1377246Antimigratory activity against PDGF-BB-stimulated rat VSMC at 15 uM preincubated for 30 mins followed by PDGF-BB addition measured after 20 hrs by scratch wound-healing assay2017Journal of natural products, 07-28, Volume: 80, Issue:7
Xanthohumol Blocks Proliferation and Migration of Vascular Smooth Muscle Cells in Vitro and Reduces Neointima Formation in Vivo.
AID638461Induction of Erk1/2 phosphorylation in human T98G cells at 20 uM measured after 24 hrs by Western blot analysis in presence of 5 mM of NAC2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID468363Induction of caspase 3 in Sprague-Dawley rat ischemic-reperfused hepatic tissue assessed as generation of free fluorescent 7-amino-4-trifluoro-methylcoumarin at 2.26 mM treated before ischemic period2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID468364Effect on ischemic and reperfusion-induced injury in Sprague-Dawley rat hepatic tissue at 2.26 mM before ischemic period assessed as ALT level2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID383189Antioxidant activity assessed as trolox equivalent at 0.25 to 1.5 uM by ORAC-fluorescein assay2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Natural and non-natural prenylated chalcones: synthesis, cytotoxicity and anti-oxidative activity.
AID1417242Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis, and evaluation of chalcone analogues incorporate α,β-Unsaturated ketone functionality as anti-lung cancer agents via evoking ROS to induce pyroptosis.
AID1378637Antiangiogenic activity in HUVEC assessed as inhibition of cell morphogenesis by measuring reduction in capillary like structure formation at 10 uM after 6 hrs by inverted microscopic method2017European journal of medicinal chemistry, Sep-29, Volume: 138Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues.
AID638398Induction of apoptosis in human T98G cells assessed as increase in ROS production at 20 uM measured every 5 mins for 5 to 120 mins by DCFH-DA staining-based flow cytometric analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1058190Antioxidant activity in streptozotocin-induced diabetic Wistar rat model assessed as increase in reduced/oxidized glutathione ratio in serum at 10 mg/L, po administered with superbock stout beer for 5 weeks prior to wounding measured on day 7 post-woundin2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing.
AID383188Cytotoxicity against human HeLa cells by MTT assay2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Natural and non-natural prenylated chalcones: synthesis, cytotoxicity and anti-oxidative activity.
AID734219Ratio of L-Ascorbic acid IC50 to compound IC50 for antioxidant activity assessed as concentration required for 50 % inhibition of micoM DPPH activity after 30 mins by UV-vis spectrophotometry2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Fungal metabolites of xanthohumol with potent antiproliferative activity on human cancer cell lines in vitro.
AID1423943Cytotoxicity in human Caco2 cells assessed as reduction in ATP metabolism at 50 to 100 uM incubated for 24 hrs by cell-titer-Glo luminescent cell viability assay2017Journal of natural products, 04-28, Volume: 80, Issue:4
Effect of Hops Derived Prenylated Phenols on TNF-α Induced Barrier Dysfunction in Intestinal Epithelial Cells.
AID638400Induction of apoptosis in human T98G cells assessed as increase in ROS production at 20 uM after 24 hrs by DCFH-DA staining-based flow cytometric analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1403209Cytotoxicity against human SGC7901 cells assessed as cell growth inhibition after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and QSAR study of novel isatin analogues inspired Michael acceptor as potential anticancer compounds.
AID738111Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Antioxidant and antiproliferative activity of glycosides obtained by biotransformation of xanthohumol.
AID1667213Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 50 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID1417243Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis, and evaluation of chalcone analogues incorporate α,β-Unsaturated ketone functionality as anti-lung cancer agents via evoking ROS to induce pyroptosis.
AID738108Antioxidant activity assessed as DPPH radical scavenging activity by by UV-vis spectrophotometry analysis2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Antioxidant and antiproliferative activity of glycosides obtained by biotransformation of xanthohumol.
AID1423949Inhibition of TNFalpha induced barrier dysfunctionin human Caco2 cells assessed as prevention of morphological changes in ZO1 protein at 10 uM pre-treated on apical side for 1 hr before TNFalpha stimulation on basolateral side for 48 hrs by confocal laser2017Journal of natural products, 04-28, Volume: 80, Issue:4
Effect of Hops Derived Prenylated Phenols on TNF-α Induced Barrier Dysfunction in Intestinal Epithelial Cells.
AID1425898Non-competitive inhibition of glucose transporter in HTR-8/SVneo cells assessed as reduction in [3H]DG uptake preincubated for 20 mins followed by [3H]DG addition after 10 mins by liquid scintillation counting method2016MedChemComm, Sep-01, Volume: 7, Issue:9
Anticancer agents interacting with membrane glucose transporters.
AID719251Inhibition of DGAT in rat liver microsomes2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Discovery of a novel series of benzimidazole derivatives as diacylglycerol acyltransferase inhibitors.
AID638296Induction of apoptosis in human T98G cells assessed as cell death at 20 uM after 48 hrs by propidium iodide staining based flow cytometric analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID663997Inhibition of human PDK1 assessed as inhibition of [33P] incorporation into substrate after 60 mins by scintillation counting2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Inverse Virtual Screening allows the discovery of the biological activity of natural compounds.
AID638285Anticancer activity against human T98G cells assessed as decrease in cell viability at 10 uM after 48 hrs by MTT assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID468353Antioxidant activity assessed as superoxide radical anion scavenging activity after 100 secs by xanthine/xanthine oxidase method2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID1667215Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 12.5 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to contr2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID1403211Growth inhibition of human NCI-H460 cells assessed as reduction in cell viability at 5 to 10 uM incubated for 24 to 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and QSAR study of novel isatin analogues inspired Michael acceptor as potential anticancer compounds.
AID1058191Antiinflammatory activity in streptozotocin-induced diabetic Wistar rat model assessed as reduction in nitric oxide level in serum at 10 mg/L, po administered with superbock stout beer for 5 weeks prior to wounding measured on day 7 post-wounding by Gries2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing.
AID1423945Effect on barrier function in human Caco2 cells assessed as LY transport at 10 uM pre-treated on apical side for 1 hr and measured after 48 hrs2017Journal of natural products, 04-28, Volume: 80, Issue:4
Effect of Hops Derived Prenylated Phenols on TNF-α Induced Barrier Dysfunction in Intestinal Epithelial Cells.
AID1379243Cytotoxicity against mouse Hepa1c1c7 cells after 48 hrs by crystal violet staining based assay2017Journal of natural products, 08-25, Volume: 80, Issue:8
DESIGNER Extracts as Tools to Balance Estrogenic and Chemopreventive Activities of Botanicals for Women's Health.
AID1403217Anti-migratory activity against human NCI-H460 cells at 10 uM incubated for 48 hrs by wound healing assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and QSAR study of novel isatin analogues inspired Michael acceptor as potential anticancer compounds.
AID1504722Cytotoxicity against mouse BV2 cells assessed as reduction in cell viability at 1 to 100 uM after 24 hrs by MTT assay2017Journal of natural products, 12-22, Volume: 80, Issue:12
Characteristic α-Acid Derivatives from Humulus lupulus with Antineuroinflammatory Activities.
AID1403208Cytotoxicity against human BGC823 cells assessed as cell growth inhibition after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and QSAR study of novel isatin analogues inspired Michael acceptor as potential anticancer compounds.
AID638399Induction of apoptosis in human T98G cells assessed as increase in ROS production at 20 uM measured every 5 mins for 5 to 120 mins by DCFH-DA staining-based flow cytometric analysis in presence of 5 mM NAC2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID468357Inhibition of ischemic and reperfusion-induced SOD activity in Sprague-Dawley rat hepatic tissue at 26.6 mM before ischemic period by pyragallol method2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID1188030Antiproliferative activity against human HMEC1 cells after 72 hrs2014European journal of medicinal chemistry, Oct-06, Volume: 85Synthesis of natural-like acylphloroglucinols with anti-proliferative, anti-oxidative and tube-formation inhibitory activity.
AID1774071Cytotoxicity against NMRI mouse MEF cells assessed as effect on cell proliferation by measuring effect on renilla activity at 10 uM incubated for 3 days by luminescence based analysis2021Journal of natural products, 10-22, Volume: 84, Issue:10
Neuroregenerative Potential of Prenyl- and Pyranochalcones: A Structure-Activity Study.
AID638465Induction of apoptosis in human T98G cells at 20 uM after 48 hrs by flow cytometric analysis pretreated with 5 uM JNK inhibitor SP600125 for 1 hr2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID486194Cytotoxicity against human HMEC1 cells assessed as cell viability after 24 hrs by MTT assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis, cytotoxicity, anti-oxidative and anti-inflammatory activity of chalcones and influence of A-ring modifications on the pharmacological effect.
AID1501518Antiinflammatory activity in ICR mouse primary peritoneal macrophages assessed as inhibition of LPS-induced IL-6 production at 10 uM pretreated for 2 hrs followed by LPS challenge measured after 22 hrs by ELISA relative to control2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of new MD2-targeted anti-inflammatory compounds for the treatment of sepsis and acute lung injury.
AID1304631Inhibition of mPGES-1 in microsomes of IL1-beta induced human A549 cells assessed as PGE2 formation by measuring enzyme residual activity at 10 uM preincubated for 15 mins followed by addition of PGH2 as substrate measured after 1 min by RP-HPLC method re2016Journal of natural products, Mar-25, Volume: 79, Issue:3
Humudifucol and Bioactive Prenylated Polyphenols from Hops (Humulus lupulus cv. "Cascade").
AID310843Antiplasmodial activity against multiresistant Plasmodium falciparum Dd2 by [3H]hypoxanthine incorporation2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
A review of anti-infective and anti-inflammatory chalcones.
AID692016Antiangiogenic activity in SV-40T transfected human HMEC1 cells assessed as inhibition of cell proliferation after 72 hrs by crystal violet staining2012Journal of natural products, Oct-26, Volume: 75, Issue:10
Bi-, tri-, and polycyclic acylphloroglucinols from Hypericum empetrifolium.
AID1199601Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Synthesis of xanthohumol analogues and discovery of potent thioredoxin reductase inhibitor as potential anticancer agent.
AID1058195Antiangiogenic activity in streptozotocin-induced diabetic Wistar rat model assessed as decrease in microvessel density in wound region at 10 mg/L, po administered with superbock stout beer for 4 weeks prior to wounding measured on day 7 post-wounding by 2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing.
AID1188031Antioxidant activity in phosphate buffer assessed as trolox equivalents ratio at pH 7.4 after 15 mins by ORAC-fluorescein assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Synthesis of natural-like acylphloroglucinols with anti-proliferative, anti-oxidative and tube-formation inhibitory activity.
AID638456Induction of p38 phosphorylation in human T98G cells at 20 uM after 30 to 60 mins for 2 hrs by Western blot analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID638389Induction of apoptosis in human T98G cells assessed as increase in caspase-3 expression level at 20 uM after 24 hrs by Western blot analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1501515Antiinflammatory activity in ICR mouse primary peritoneal macrophages assessed as inhibition of LPS-induced TNF-alpha production at 10 uM pretreated for 2 hrs followed by LPS challenge measured after 22 hrs by ELISA relative to control2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of new MD2-targeted anti-inflammatory compounds for the treatment of sepsis and acute lung injury.
AID638392Induction of apoptosis in human T98G cells assessed as increase in mitochondrial depolarization at 20 uM by TREM fluorescence analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1087278Antiproliferative activity against Homo sapiens (human) HT-29 cells after 72 hr by SRB assay2012Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, Dec, Volume: 21, Issue:12
Antiproliferative activity and synthesis of 8-prenylnaringenin derivatives by demethylation of 7-O- and 4'-O-substituted isoxanthohumols.
AID1087279Antiproliferative activity against Homo sapiens (human) MCF7 cells after 72 hr by SRB assay2012Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, Dec, Volume: 21, Issue:12
Antiproliferative activity and synthesis of 8-prenylnaringenin derivatives by demethylation of 7-O- and 4'-O-substituted isoxanthohumols.
AID1058194Antiangiogenic activity in streptozotocin-induced diabetic Wistar rat model assessed as reduction in VEGF-A level in plasma at 10 mg/L, po administered with superbock stout beer for 5 weeks prior to wounding measured on day 7 post-wounding by ELISA2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing.
AID1705465Stabilization of TTR V30M mutant (unknown origin) assessed as inhibition of protein-mediated amyloid fibril formation2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments.
AID638464Induction of apoptosis in human T98G cells at 20 uM after 48 hrs by flow cytometric analysis pretreated with 5 uM p38 inhibitor SB203580 for 1 hr2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1423946Increase in transepithelial electrical resistance in human Caco2 cells at 10 uM pre-treated on apical side and measured after 36 to 72 hrs2017Journal of natural products, 04-28, Volume: 80, Issue:4
Effect of Hops Derived Prenylated Phenols on TNF-α Induced Barrier Dysfunction in Intestinal Epithelial Cells.
AID638404Induction of apoptosis in human T98G cells assessed as decrease in mitochondrial depolarization at 20 uM after 24 hrs by TREM fluorescence analysis in presence of 5 mM NAC2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID638467Induction of apoptosis in human T98G cells after 48 hrs by propidium iodide staining-based flow cytometric analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1058196Antioxidant activity in streptozotocin-induced diabetic Wistar rat model assessed as reduction in hepatic protein carbonylation at 10 mg/L, po administered with superbock stout beer for 5 weeks prior to wounding measured on day 7 post-wounding by Western 2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing.
AID738110Antiproliferative activity against human PC3 cells after 72 hrs by SRB assay2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Antioxidant and antiproliferative activity of glycosides obtained by biotransformation of xanthohumol.
AID638391Induction of apoptosis in human T98G cells assessed as increase in cleaved PARP protein level at 20 uM after 24 hrs by Western blot analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID638401Induction of apoptosis in human T98G cells assessed as increase in ROS production at 20 uM after 24 hrs by DCFH-DA staining-based flow cytometric analysis in presence of 5 mM NAC2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1290737Binding affinity to recombinant human MD2 (17 to 160 residues) expressed in Escherichia coli BL21(DE3) cells by surface plasmon resonance analysis2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Discovery of a New Inhibitor of Myeloid Differentiation 2 from Cinnamamide Derivatives with Anti-Inflammatory Activity in Sepsis and Acute Lung Injury.
AID638405Induction of apoptosis in human T98G cells assessed as decrease in Bcl-2 expression at 20 uM after 48 hrs by Western blot analysis in presence of 5 mM NAC2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID468360Inhibition of TNF-alpha-induced NF-kappaB activation expressed in human HEK293 cells preincubated for 2 hrs before TNFalpha challenge by leuciferase reporter gene assay2009Journal of natural products, Oct, Volume: 72, Issue:10
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury.
AID376752Inhibition of LPS/IFN-gamma-induced NO production in mouse RAW264.7 cells after 16 hrs2005Journal of natural products, Jan, Volume: 68, Issue:1
Prenylflavonoids and phloroglucinol derivatives from hops (Humulus lupulus).
AID638463Induction of apoptosis in human T98G cells at 20 uM after 48 hrs by flow cytometric analysis pretreated with 20 uM Erk inhibitor PD98059 for 30 mins2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1377245Cytotoxicity against rat VSMC at 1 to 15 uM after 48 hrs by LDH release assay2017Journal of natural products, 07-28, Volume: 80, Issue:7
Xanthohumol Blocks Proliferation and Migration of Vascular Smooth Muscle Cells in Vitro and Reduces Neointima Formation in Vivo.
AID638284Anticancer activity against human T98G cells assessed as decrease in cell viability after 48 hrs by MTT assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID1378636Anti-invasive activity in HUVEC at 10 uM after 24 hrs by DAPI staining based Boyden chamber method2017European journal of medicinal chemistry, Sep-29, Volume: 138Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues.
AID310842Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum poW by [3H]hypoxanthine incorporation2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
A review of anti-infective and anti-inflammatory chalcones.
AID734218Cytotoxicity against human PC3 cells after 72 hrs by SRB assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Fungal metabolites of xanthohumol with potent antiproliferative activity on human cancer cell lines in vitro.
AID1058186Antioxidant activity in streptozotocin-induced diabetic Wistar rat model assessed as reduction in 3-NT protein expression in kidney at 10 mg/L, po administered with superbock stout beer for 5 weeks prior to wounding measured on day 7 post-wounding by West2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing.
AID734216Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Fungal metabolites of xanthohumol with potent antiproliferative activity on human cancer cell lines in vitro.
AID638393Induction of apoptosis in human T98G cells assessed as increase in mitochondrial depolarization at 20 uM after 4 hrs by TREM fluorescence analysis2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
AID734220Antioxidant activity assessed as concentration required for 50 % inhibition of micoM DPPH activity after 30 mins by UV-vis spectrophotometry2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Fungal metabolites of xanthohumol with potent antiproliferative activity on human cancer cell lines in vitro.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (401)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (1.00)18.2507
2000's87 (21.70)29.6817
2010's216 (53.87)24.3611
2020's94 (23.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.59 (24.57)
Research Supply Index6.04 (2.92)
Research Growth Index6.08 (4.65)
Search Engine Demand Index80.94 (26.88)
Search Engine Supply Index2.93 (0.95)

This Compound (38.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (2.70%)5.53%
Reviews22 (5.39%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other375 (91.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Micellar Solubilized Xanthohumol on Resting Energy Expenditure and Substrate Oxidation in Healthy Women [NCT05711212]8 participants (Anticipated)Interventional2023-02-15Recruiting
Plasmakinetics of Micellar Solubilized Xanthohumol in Metabolically Healthy Men and Women [NCT05524714]12 participants (Actual)Interventional2022-08-01Completed
Xanthohumol and Metabolic Syndrome [NCT01367431]48 participants (Actual)Observational2011-08-31Completed
A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease [NCT04590508]Phase 232 participants (Anticipated)Interventional2020-10-01Recruiting
Xanthohumol Metabolism and Signature (XMaS) in Healthy Adults [NCT03735420]Phase 130 participants (Actual)Interventional2019-08-12Active, not recruiting
Prevention of Oxidative DNA Damage by Xanthohumol [NCT02432651]Phase 164 participants (Actual)Interventional2015-03-31Completed
Humulus Lupus Extract Rich in Xanthohumol Improves Clinical Course in Critically Ill COVID-19 Patients [NCT05463393]Early Phase 150 participants (Anticipated)Interventional2020-10-01Suspended(stopped due to We are waiting for the additional founds.)
Effect of Iso-alpha-Acids and Xanthohumol on Inflammatory Processes in Human [NCT04847193]15 participants (Actual)Interventional2019-06-13Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03735420 (16) [back to overview]Alanine Aminotransferase (ALT)
NCT03735420 (16) [back to overview]Aspartate Aminotransferase (AST)
NCT03735420 (16) [back to overview]Blood Urea Nitrogen to Creatinine Ratio
NCT03735420 (16) [back to overview]Change in Levels of Metabolic Byproducts of Xanthohumol: Plasma and Urine
NCT03735420 (16) [back to overview]Change in Plasma Inflammatory Markers
NCT03735420 (16) [back to overview]Complete Blood Count Abnormals
NCT03735420 (16) [back to overview]Estimated Glomerular Filtration Rate
NCT03735420 (16) [back to overview]Gamma-Glutamyl Transferase (GGT)
NCT03735420 (16) [back to overview]Gut Inflammation
NCT03735420 (16) [back to overview]Hematocrit
NCT03735420 (16) [back to overview]Incidence of Intervention-attributable Adverse Events [Safety and Tolerability]
NCT03735420 (16) [back to overview]Mean Corpuscular Hemoglobin
NCT03735420 (16) [back to overview]Mean Corpuscular Volume
NCT03735420 (16) [back to overview]Platelet Count
NCT03735420 (16) [back to overview]Total Red Blood Cell Count
NCT03735420 (16) [back to overview]Total White Blood Cell Count

Alanine Aminotransferase (ALT)

Alanine aminotransferase is an enzyme that is often measured in blood as an indication of liver toxicity. Reported as mean change from baseline. (NCT03735420)
Timeframe: 2 weeks, 4 weeks, 6 weeks, and 8 weeks.

,
Interventionmilligrams per decileter (mg/dL) (Mean)
Week 2Week 4Week 6Week 8
Placebo Oral Capsule14.914.015.412.9
Xanthohumol18.016.116.415.1

[back to top]

Aspartate Aminotransferase (AST)

Aspartate aminotransferase is an enzyme that is often measured in blood as an indication of liver toxicity. Reported as mean change from baseline. (NCT03735420)
Timeframe: 2 weeks, 4 weeks, 6 weeks, and 8 weeks.

,
Interventionmilligrams per deciliter (mgdL) (Mean)
Week 2Week 4Week 6Week 8
Placebo Oral Capsule15.415.316.415.5
Xanthohumol22.918.321.118.4

[back to top]

Blood Urea Nitrogen to Creatinine Ratio

Blood urea nitrogen (BUN) : creatinine (Cr) is a ratio of serum concentrations of two compounds associated with renal function. Reported as mean change from baseline. (NCT03735420)
Timeframe: 2 weeks, 4 weeks, 6 weeks, and 8 weeks.

,
InterventionRatio of BUN (mg/dL) to Cr (mg/dL) (Mean)
BaselineWeek 2Week 4Week 6Closeout
Placebo Oral Capsule15.616.415.214.814.5
Xanthohumol14.515.515.314.514.7

[back to top]

Change in Levels of Metabolic Byproducts of Xanthohumol: Plasma and Urine

Xanthohumol and xanthohumol metabolites in blood, urine and stool, will be measured by ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry. Metabolites include 6-prenylnaringenin (6-PN), 8-prenylnaringenin (8-PN), dihydroxanthohumol (DXN), desmethyldihydroxanthohumol (DDXN), isoxanthohumol (IXN), and xanthohumol (XN). The measures were assessed at Baseline, 2 weeks, 4 weeks, 6 weeks, and 8 weeks; baseline, weeks 2, 4, 6, and 8 reported for urine and plasma. (NCT03735420)
Timeframe: Baseline, 2 weeks, 4 weeks, 6 weeks, and 8 weeks.

,
Interventionnanograms per millileter (ng/mL) (Mean)
Urinary 6-Prenylnaringenin (6-PN): BaselineUrinary 6-PN: Week 2Urinary 6-PN: Week 4Urinary 6-PN: Week 6Urinary 6-PN: Week 8Urinary 8-Prenylnaringenin (8-PN): BaselineUrinary 8-PN: Week 2Urinary 8-PN: Week 4Urinary 8-PN: Week 6Urinary 8- PN Week 8Urinary Dihydroxanthohumol (DXN): BaselineUrinary DXN: Week 2Urinary DXN: Week 4Urinary DXN: Week 6Urinary DXN: Week 8Urinary Desmethyldihydroxanthohumol (DDXN): BaselineUrinary DDXN: Week 2Urinary DDXN: Week 4Urinary DDXN: Week 6Urinary DDXN: Week 8Urinary Isoxanthohumol (IXN): BaselineUrinary IXN: Week 2Urinary IXN: Week 4Urinary IXN: Week 6Urinary IXN: Week 8Urinary Xanthohumol (XN) BaselineUrinary XN: Week 2Urinary XN: Week 4Urinary XN: Week 6Urinary XN: Week 8Plasma 6-Prenylnaringenin (6PN): BaselinePlasma 6-PN: Week 2Plasma 6-PN: Week 4Plasma 6-PN: Week 6Plasma 6-PN: Week 8Plasma 8-Prenylnaringenin: BaselinePlasma 8-PN: Week 2Plasma 8-PN: Week 4Plasma 8-PN: Week 6Plasma 8-PN: Week 8Plasma Dihydroxanthohumol (DXN): BaselinePlasma DXN: Week 2Plasma DXN: Week 4Plasma DXN: Week 6Plasma DXN: Week 8Plasma Desmethyldihydroxanthohumol (DDXN): BaselinePlasma DDXN: Week 2Plasma DDXN: Week 4Plasma DDXN: Week 6Plasma DDXN: Week 8Plasma Isoxanthohumol (IXN): BaselinePlasma IXN: Week 2Plasma IXN: Week 4Plasma IXN: Week 6Plasma IXN: Week 8Plasma Xanthohumol (XN): BaselinePlasma XN: Week 2Plasma XN: Week 4Plasma XN: Week 6Plasma XN: Week 8
Placebo Oral Capsule0000001.412000.086000.0160000.023.2992.121.494.281.48404.666.1240000000000000007.288000000.2750000.3651.3250.8220
Xanthohumol00.5910006.8116.5887.1964.7250.562.561.4102.043.042.041.0360.0712.23794.120103.92066.62895.7561.95221.28014.90819.97919.952000001.3021.503.8401.0011.3020.9680000000007.8646.9996.1408.17407.1566.7845.8105.796

[back to top]

Change in Plasma Inflammatory Markers

Circulating pro-inflammatory cytokine concentrations (tumor necrosis factor (TNF)-α, interleukin (IL)-1 beta, IL-6, IL-8, IL-10, and IL-12p70), will be measured simultaneously with a flow cytometry-based multiplex assay. The measures were assessed at Baseline, 2 weeks, 4 weeks, 6 weeks, and 8 weeks; weeks 2, 4, 6, and 8 reported (NCT03735420)
Timeframe: 2 weeks, 4 weeks, 6 weeks, and 8 weeks.

,
Interventionpicogram per milliliter (pg/mL) (Mean)
Week 2: Interleukin 1-beta (IL-1b)Week 4: IL-1bWeek 6: IL-1bWeek 8: IL-1bWeek 2: Interleukin 6 (IL-6)Week 4: IL-6Week 6: IL-6Week 8: IL-6Week 2: Interleukin 8 (IL-8)Week 4: IL-8Week 6: IL-8Week 8: IL-8Week 2: Interleukin 10 (IL-10)Week 4: IL-10Week 6: IL-10Week 8: IL-10Week 2: Interleukin 12p70 (IL-12p70)Week 4: IL-12p70Week 6: IL-12p70Week 8: IL-12p70Week 2: Tumor Necrosis Factor Alpha (TNFa)Week 4: TNFaWeek 6: TNFaWeek 8: TNFa
Placebo Oral Capsule2201722368-133-54-79-5135651796-727626397610-2-323-212-3-4-1
Xanthohumol-2463-3153-620-3624-784-684-764-784-59147669-6955-6882-46-34-49-4325-7-140-8-28-23-25

[back to top]

Complete Blood Count Abnormals

Enumeration of the various subtypes of blood cells (i.e., red blood cells, white blood cells, and platelets), plus indices including mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), and hematocrit. Reported as: % abnormal (i.e., number of participants with an abnormal value compared to the number of participants in the group) and % new abnormals if abnormal counts were noted. Abnormality is assessed according to standards for age and sex measurements under Quest Diagnostics criteria. (NCT03735420)
Timeframe: 2 weeks, 4 weeks, 6 weeks, and 8 weeks.

,
Interventionparticipants (Number)
Total Red Blood Cell Count (Week 4): number of abnormalsTotal Red Blood Cell Count (Week 4) : number of new abnormalsTotal Red Blood Cell Count (Week 8) : number of abnormalTotal Red Blood Cell Count (Week 8) : number of new abnormalsMean Corpuscular Hemoglobin (Week 8) : number of abnormalsMean Corpuscular Hemoglobin (Week 8) : number of new abnormalsHemoglobin (Week 2) : number of abnormalsHemoglobin (Week 2) : number of new abnormalsHemoglobin (Week 4) : number of abnormalsHemoglobin (Week 4) : number of new abnormalsHemoglobin (Week 6) : number of abnormalsHemoglobin (Week 6) : number of new abnormalsHemoglobin (Week 8) : number of abnormalsHemoglobin (Week 8) : %new abnormalsTotal White Blood Cell Count (Week 2) : number of abnormalsTotal White Blood Cell Count (Week 2) : number of new abnormalsTotal White Blood Cell Count (Week 4) : number of abnormalsTotal White Blood Cell Count (Week 4) : number of new abnormalsTotal White Blood Cell Count (Week 6) : number of abnormalsTotal White Blood Cell Count (Week 6) : number of new abnormalsTotal White Blood Cell Count (Week 8) : number of abnormalTotal White Blood Cell Count (Week 8) : %new abnormals
Placebo Oral Capsule1111002121213220203110
Xanthohumol1100110022110033112211

[back to top]

Estimated Glomerular Filtration Rate

Glomerular filtration rate is estimated based on blood creatinine concentration per standard nephrology practice. Reported as mean change from baseline. (NCT03735420)
Timeframe: 2 weeks, 4 weeks, 6 weeks, and 8 weeks

,
Interventionmillileters per minute (mL/min) (Mean)
Week 2Week 4Week 6Week 8
Placebo Oral Capsule112.0111.8111.4111.8
Xanthohumol108.7110.6109.2108.4

[back to top]

Gamma-Glutamyl Transferase (GGT)

Gamma-glutamyl transferase is an enzyme that is often measured in blood as an indication of liver toxicity. Reported as mean change from baseline. (NCT03735420)
Timeframe: Baseline, 2 weeks, 4 weeks, 6 weeks, and 8 weeks

,
Interventionmilligrams per decileter (mg/dL) (Mean)
Week 2Week 4Week 6Week 8
Placebo Oral Capsule11.811.812.311.8
Xanthohumol12.112.312.912.1

[back to top]

Gut Inflammation

Fecal calprotectin, a protein associated with gut inflammation and irritable gut syndrome, will be measured by enzyme-linked immunosorbent assay, and expressed as mean change over time from baseline. (NCT03735420)
Timeframe: Baseline, 2 weeks, 4 weeks, 6 weeks, and 8 weeks.

,
Interventionmicrogram per milligram (ug/mg) (Mean)
BaselineWeek 2Week 4Week 6Week 8
Placebo Oral Capsule35.219.912.714.313.2
Xanthohumol12.812.413.412.715.2

[back to top]

Hematocrit

Enumeration of hematocrit. Results are reported as mean change from baseline at weeks 2, 4, 6, and 8. (NCT03735420)
Timeframe: 2 weeks, 4 weeks, 6 weeks, and 8 weeks.

,
Interventionpercent (%) (Mean)
Hematocrit (Week 2)Hematocrit (Week 4)Hematocrit (Week 6)Hematocrit (Week 8)
Placebo Oral Capsule0.77-0.20-0.32-0.03
Xanthohumol0.480.230.570.44

[back to top]

Incidence of Intervention-attributable Adverse Events [Safety and Tolerability]

"Self-reported adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events. Reported as: New onset FDA serious adverse events (Grade 1); New onset moderate adverse events (Grade 2). The measures were assessed at Baseline, 2 weeks, 4 weeks, 6 weeks, and 8 weeks; weeks 2, 4, 6, and 8 reported." (NCT03735420)
Timeframe: Baseline, 2 weeks, 4 weeks, 6 weeks, and 8 weeks.

,
InterventionAdverse events (Number)
Week 2 Grade 1Week 2 Grade 2Week 4 Grade 1Week 4 Grade 2Week 6 Grade 1Week 6 Grade 2Week 8 Grade 1Week 8 Grade 2
Placebo Oral Capsule929311202
Xanthohumol12218018852

[back to top]

Mean Corpuscular Hemoglobin

Enumeration of mean corpuscular hemoglobin (MCH). Results are reported as mean change from baseline at weeks 2, 4, 6, and 8. (NCT03735420)
Timeframe: 2 weeks, 4 weeks, 6 weeks, and 8 weeks.

,
Interventionpicograms (pg) (Mean)
Mean Corpuscular Hemoglobin (Week 2)Mean Corpuscular Hemoglobin (Week 4)Mean Corpuscular Hemoglobin (Week 6)Mean Corpuscular Hemoglobin (Week 8)
Placebo Oral Capsule0.050.260.290.20
Xanthohumol-0.06-0.04-0.13-0.23

[back to top]

Mean Corpuscular Volume

Enumeration of mean corpuscular volume (MCV). Results are reported as mean change from baseline at weeks 2, 4, 6, and 8. (NCT03735420)
Timeframe: 2 weeks, 4 weeks, 6 weeks, and 8 weeks.

,
Interventionfemtoliter (fL) (Mean)
Mean Corpuscular Volume (Week 2)Mean Corpuscular Volume (Week 4)Mean Corpuscular Volume (Week 6)Mean Corpuscular Volume (Week 8)
Placebo Oral Capsule.14.61.04.04
Xanthohumol.20-0.27-0.25-0.63

[back to top]

Platelet Count

Enumeration of platelet count. Results are reported as mean change from baseline at weeks 2, 4, 6, and 8. (NCT03735420)
Timeframe: 2 weeks, 4 weeks, 6 weeks, and 8 weeks.

,
Interventionthousand cells per microliter (1000/uL) (Mean)
Platelet Count (Week 2)Platelet Count (Week 4)Platelet Count (Week 6)Platelet Count (Week 8)
Placebo Oral Capsule3.543.4614.0010.46
Xanthohumol2.600.0722.937.14

[back to top]

Total Red Blood Cell Count

Enumeration of total red blood cell count. Reported as mean change from baseline. (NCT03735420)
Timeframe: Baseline, 2 weeks, 4 weeks, 6 weeks, and 8 weeks.

,
Interventionmean change from baseline (Mean)
Total Red Blood Cell Count (Week 2)Total Red Blood Cell Count (Week 4)Total Red Blood Cell Count (Week 6)Total Red Blood Cell Count (Week 8)
Placebo Oral Capsule.08-.06-.04.00
Xanthohumol.04.04.07.08

[back to top]

Total White Blood Cell Count

Enumeration of total white blood cell count. Results are reported as mean change from baseline at weeks 2, 4, 6, and 8. (NCT03735420)
Timeframe: 2 weeks, 4 weeks, 6 weeks, and 8 weeks.

,
Interventionthousand cells per microliter (1000/uL) (Mean)
Total White Blood Cell Count (Week 2)Total White Blood Cell Count (Week 4)Total White Blood Cell Count (Week 6)Total White Blood Cell Count (Week 8)
Placebo Oral Capsule-.05-.05.23.21
Xanthohumol-.59-.09-.24-.24

[back to top]